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“Imagination is more important than knowledge.  
For knowledge is limited to all we now know and understand,  
while imagination embraces the entire world,  
and all there ever will be to know and understand”  
 
Albert Einstein 
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ABSTRACT 
 
 
Alzheimer's disease (AD) is a fatal neurodegenerative condition characterized 
clinically by progressive memory loss and irreversible cognitive deterioration. It has 
been shown that there is a progressive degeneration of the brain cholinergic neurons 
which leads to the appearance of cognitive symptoms of the disease. At present, there 
are no therapeutic interventions able to stop the progression nor to treat brain 
degeneration. Treatments are therefore aimed at slowing down the worsening course, 
maintaining, at least temporarily, the cognitive and behavioural symptoms, thus 
ensuring patients to have good or decent quality of life. One strategy to combat this 
disease is to increase cholinergic transmission; therefore acetylcholinesterase 
inhibitors have been developed including tacrine, rivastigmine and donepezil.  
Tacrine hydrochloride (1,2,3,4-tetrahydro-9-aminoacridine mono hydrochloride) 
(THA), a potent, centrally active, reversible cholinesterase inhibitor, was the first 
drug approved by the United States Food and Drug Administration (FDA) in 1993 
for treating the symptoms of mild to moderate Alzheimer disease. THA is available 
in the market as oral capsule dosage forms. Despite the favourable aqueous 
solubility, peroral administration of THA is associated with low bioavailability due 
to hepatic first-pass effect, short elimination half-life, gastrointestinal side effect and 
reversible dose-dependent hepatotoxicity, the major reasons for its withdrawal. 
Hence, alternative routes of administration for the centrally active 
acetylcholinesterase inhibitor tacrine may offer distinct advantages.  
Drug delivery from the nose to the Central Nervous System (CNS) can be achieved 
via olfactory neuroepithelium and can involve paracellular (inter cellular spaces and 
tight junction), transcellular (passive diffusion, active transport and transcytosis) 
and/or neuronal transport. Moreover, the transport via trigeminal nerve system from 
the nasal cavity to CNS has also been described. THA delivery into CNS through 
intranasal route has been reported either in humans or animal models of Alzheimer’s 
disease and its administration by intranasal route not only has been found useful for 
   
circumventing the blood-brain barrier, but also for avoiding the hepatic first-pass 
effect, thus allowing lower dosage and side effects. 
In this thesis THA delivery from the nose to the CNS was investigated using two 
multifunctional nanocarriers:  
 Albumin nanoparticles carrying beta cyclodextrin and two different beta 
cyclodextrin derivatives (hydroxypropyl beta cyclodextrin and sulphobutylether 
beta cyclodextrin). Bovine serum albumin nanoparticles were obtained using a 
coacervation method, followed by thermal cross-linking, starting from protein 
solution at alkaline pH. After preparation, nanoparticles were loaded by soaking 
from solutions of tacrine hydrochloride and lyophilized. Thermal analysis 
(Differential Scanning Calorimetry and Thermogravimetric analysis) supported 
by Fourier Transform Infrared Spectroscopy were performed in order to confirm 
protein cross-linking in nanosphere structure and possible drug/carrier interaction 
occurred after the loading process. Moreover, size, polydispersity, zeta potential 
and morphology of the nanoparticles were investigated as well as drug loading, 
mucoadhesion properties and ex-vivo drug permeation ability. Results indicate 
that all the nanoparticles presented a mean size and a polydispersity lower than 
300 nm and 0.33 respectively, were spherical shaped and negatively charged 
even after drug loading. Moreover, the presence of the different beta 
cyclodextrins in the polymeric network affected drug loading and could 
differently modulate nanoparticle mucoadhesiveness and drug permeation 
behaviour.  
 Multifunctional liposomes, prepared using traditional excipients (cholesterol and 
phosphatidylcholine), partly enriched with α-tocopherol (Toc) and/or 
polyunsaturated fatty acids (eicosapentaenoic acid and docosahexaenoic acid) 
(Ω3). The aim with these special ingredients was to increase drug bioavailability, 
possibly due to enhanced liposome fusion with mucosal epithelial cells and, at 
the same time, to improve the therapeutic effect due to their antioxidant and anti-
inflammatory properties. Here, several liposome formulations were prepared 
using the reverse phase evaporation technique followed by membrane filter 
extrusion. In particular, liposome capacity to enhance drug permeation was 
evaluated by means of different assays: Ex-vivo Nasal Sheep Permeation Assay 
   
(ENSPA), Phospholipid Vesicle based barrier Permeation Assay (PVPA) and 
Uptake Studies in Human Neuronal Cell (USHNC). All liposome formulations 
showed a mean diameter in the range of 175 nm to 219 nm with polydispersity 
index lower than 0.22, a lightly negative zeta potential and excellent 
encapsulation efficiency.  Moreover, along with good mucoadhesive properties, 
liposomes containing Toc and Ω3 showed markedly increased tacrine 
permeability which may be due to fusion of liposomes with cellular membrane, a 
hypothesis, which is also supported by cellular uptake studies. Muntifunctional 
liposomes have high potential as new systems for CNS-delivery of anti-
Alzheimer drugs via the nasal route. In the last part of the thesis are reported the 
antioxidant and neuroprotective properties of our multifunctional liposomes. 
Particularly, liposome formulations and THA solution at different concentrations 
were tested to evaluate possible neurotoxicity, neuroprotection, antioxidant effect 
and reduction of ROS production in the neurons, using human neuronal cell line 
SH-SY5Y. The MTT assay confirmed the non-toxicity of all liposome 
formulation. Caspase-3 test showed that the formulations containing Toc and 
especially those containing both Toc and Ω3 presented markedly neuroprotective 
effect, reducing the activation of apoptosis initiator enzyme (caspase 3), after 
treatment with hydrogen peroxide. The intracellular ROS generation (in neurons) 
was investigated using the 2’,7’-dichlorfluorescein-diacetate (DCFH-DA) as a 
well-established compound to detect and quantify intracellular produced H2O2. 
Also in this case,  liposomes containing Toc and Ω3 showed a better activity than 
other formulations. In conclusion, liposomes enriched with Toc and Ω3 presented 
the best permeation profile and antioxidant activity, even when compared to 
liposomes containing Toc alone. To explain this behaviour, Tocopherol 
intermembrane tranfer was evaluated confirming that Ω3 can enhance the 
intermembrane Toc diffusion. 
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1. AN OVERVIEW ON ALZHEIMER’S DISEASE 
 
 
Alzheimer’s disease (AD) the most common form of dementia among older people, 
it is characterized by the breakdown of connections between neurons and their 
eventual death [1]. AD is taking on the contours of a global epidemic, latest 
estimates tell us that more than 35 million people worldwide are living with 
dementia. Unless we can change the course of this disease, this number is expected 
to double by 2030 and more than triple by 2050. Has been reported in the Journal of 
Alzheimer’s association that in the United States [2], AD is the sixth leading cause of 
all deaths and is the fifth leading cause of death in Americans aged 65 years. An 
estimated 5.4 million Americans have AD; every 69 seconds, someone in America 
develops AD; by 2050, the time is expected to accelerate to every 33 seconds. Over 
the coming decades, the baby boom population is projected to add 10 million people 
to these numbers. In 2050, the incidence of AD is expected to approach nearly a 
million people per year, with a total estimated prevalence of 11 to 16 million people. 
Dramatic increases in the numbers of “oldest-old” (those aged 85 years) across all 
racial and ethnic groups will also significantly affect the numbers of people living 
with AD. In 2010, nearly 15 million family and other unpaid caregivers provided an 
estimated 17 billion hours of care to people with AD and other dementias, a 
contribution valued at more than $202 billion. Medicare payments for services to 
beneficiaries aged 65 years with AD and other dementias are almost 3 times higher 
than for beneficiaries without these conditions. Total payments in 2011 for health 
care, long-term care, and hospice services for people aged 65years with AD and 
other dementias are expected to be $183 billion (not including the contributions of 
unpaid caregivers) [3].  
This heterogeneous, progressive disease of the central nervous system still is of 
unknown etiology with the exception of the rare familial cases of autosomal-
dominant inheritance of gene defects. The two main types of AD currently 
1. An overview on Alzheimer’s disease
 
 
   Giuseppe Corace                                     Page 22 of 130                                  University of Bologna      
recognized are a generally later-onset sporadic form, representing about 95% of all 
cases, and autosomal-dominant familial forms involving specific mutations in one of 
three genetic loci (APP, presenilin 1, and presenilin 2) and typically associated with 
the early-onset of AD symptoms. Neuropathological examination of the AD brain 
shows the presence of characteristic markers such as  intraneuronal neurofibrillary 
tangles (NFTs) composed of hyperphosphorylated tau protein and senile plaques, 
which are due to the deposition of amyloid-β peptides (Aβ), derived from the altered 
cleavage, operated by β- and γ-secretases,  on the Aβ precursor protein (APP), 
resulting in over production and aggregation of neurotoxic forms of Aβ. The 
relationships between Aβ and the pathogenesis of the disease seems well established. 
In fact, Aβ aggregates are neurotoxic and also promote the  hyperphosphorylation of 
tau protein, thus causing before neuronal dysfunction and subsequently neuron death 
[4-6].  
 
 
 
Fig. 1.1   Alzheimer’s hallmarks © 2000 - 2012 American Health Assistance Foundation 
 
 
Moreover, the possibility that soluble forms of Aβ, including profibrils and 
oligomers, may also be more toxic than Aβ, has recently been taken into account. In 
NORMAL ALZHEIMER’S 
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fact, the presence of soluble Aβ increases the caspases activation [7]. Caspases are a 
family of serine-aspartyl proteases whose activation normally leads to cell apoptosis. 
Caspases are involved in the cleavage of numerous proteins, including APP, 
presenilin (PS1, PS2) and tau [8,9], which, as mentioned above, are involved in AD.  
Recently, has been shown that their activation does not necessarily conduct neurons 
to the apoptosis process; in fact, caspases can be activated for long time without 
neuronal death [10] carrying out their deleterious actions on neurons and promoting 
the AD progression [5]. Based on these notions, oxidative stress (OS) is increasingly 
taking a key role in the pathogenesis and progression of several neurodegenerative 
disorders including AD. OS and Aβ are closely intertwined; particularly, OS 
increases the production of Aβ [11], due to the increase of β-secretase, γ-secretase  
 
 
 
and APP protein expression and activity [12], and Aβ promotes OS in-vivo and in-
vitro [13], creating a vicious cycle that forwards the disease (Fig. 1.2). In addition, is 
Fig.  1.2  Implication of the ROS in the pathogenesis of AD 
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well known that reactive oxygen species (ROS) activate the caspases with everything 
that goes with it.  
One of the first clinical manifestations of AD include the gradual progression of 
cognitive impairment affecting multiple domains. The clinical hallmark of AD 
includes the impaired recent memory like difficulty learning new information; 
moreover, it can also occur disturbances in language, apraxia, mental confusion, 
behavioural changes and loss of executive control functions such as insight and 
judgment14]. Despite the causes of this disease are still obscure, it is seen that the 
cognitive impairment is closely related to a destruction of cholinergic neurons and a 
deficiency of acetylcholine (Ach) at the level of the hippocampus a structure of the 
brain essential for memory and learning “cholinergic hypothesis”. Regarding the 
decrease in central cholinergic activity has been given the most attention for the 
treatment of disease; in fact, the initial pharmacologic strategy for AD is focused on 
increasing cholinergic transmission in the brain[15]. Among different strategies 
employed to increase synaptic levels of Ach, there is the inhibition of the  
neurotransmitter degradation, using acetylcholinesterase inhibitors (AChEIs) or 
butyrylcholinesterase inhibitors (BuChEIs), this last enzyme is a minor constituent in 
normal brains but in the brains of AD patients is increased in association with 
plaques and tangles, so its inhibition is very important to improve cholinergic 
transmission. Among the cholinesterase inhibitors approved, there are tacrine 
hydrochloride (tacrine) and rivastigmine tartrate (rivastigmine) that act on both 
AChE  and BuChE, donepezil hydrochloride (donepezil ) which instead inhibits only  
AchE and galantamine hydrochloride (galantamine) that besides the 
acetylcholinesterase inhibitor activity has also an allosteric nicotinic receptor 
modulator (NRM) activity, which has been shown to stimulate the presynaptic 
release of acetylcholine and other neurotransmitters in laboratory preparations. In 
addition to cholinergic hypothesis has been recently highlighted the implication of 
excitatory neurotransmitter glutamate in the pathogenesis of AD; on the basis of this, 
has been inserted in the pharmaceutical treatment of the disease  also  the class of 
NMDA antagonist, of which the only commercially available drug is the memantine 
hydrochloride (memantine). Neuropharmacologic and pharmacokinetic properties of 
the currently available anti-Alzheimer drug are summarized in Table 1.1. 
1. An overview on Alzheimer’s disease
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Table 1.1   Anti-Alzheimer drug available on the market [15] 
 
  
Tacrine 
(Cognex®) 
 
Donepezil 
(Aricept®) 
 
Rivastigmine 
(Exelon®) 
 
 
Galantamine 
(Razadyne®) 
(RazadyneER®) 
 
 
Memantine 
(Namenda™) 
 
Manufacturer/ 
Distributor 
West-Ward 
Horizon 
Eisai 
Pfizer 
Novartis 
Janssen 
Shire 
Merz 
Forest 
Mechanism(s) 
 
AChEI, 
BuChEI 
 
AChEI 
 
AChEI, BuChEI AChEI, NRM 
 
 
NMDA 
antagonist 
 
Dose Forms 
(mg) 
 
10, 20, 30, 
40 
5, 10 1.5, 3, 4.5, 6 
 
 
4, 8, 12 
4mg/ml 
8, 16, 24 
 
5, 10 
 
Dose 
Frequency 
 
4x /day 
 
 
1x /day 
 
2x /day 
 
2x /day 
1x /day 
2x /day 
Serum T½  
(hrs) 
 
1.3 – 2 
 
 
70 
 
2 – 8 6 – 8 60 – 80 
Dose Range 
 
40 – 160 
mg/d 
5 – 10 mg/d 3 – 12 mg/d 8 – 24 mg/d 5 – 20 mg/d 
Target Dose 
 
80 – 160 
mg/d 
5 – 10 mg/d 6 – 12 mg/d 16 – 24 mg/d 10 – 20 mg/d 
Dose Titration 6 wks. 4 – 6 wks. 4 – 6 wks. 4 wks. 1 wk. 
Metabolism 
 
CYP1A2 
 
 
 
CYP2D6, 
3A4 
 
 
Non-hepatic 
 
CYP2D6,3A4 Non-hepatic 
Protein-binding 75% 96% 40% 
 
18-19% 
 
45% 
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Tacrine 
(Cognex®) 
 
Donepezil 
(Aricept®) 
 
Rivastigmine 
(Exelon®) 
 
 
Galantamine 
(Razadyne®) 
(RazadyneER®) 
 
 
Memantine 
(Namenda™) 
 
Taken with 
food 
Yes Not necessary Yes Yes Not necessary 
Hepatotoxicity Yes No No No No 
Table  1.1  Continued 
 
These drugs do not stop the evolutionary process of the disease but are only able to 
determine the significant improvement of cognitive performance and a gradual 
slowing of the functional deficit, but their side effects often require discontinuation 
of treatment.  For this reason, today, many studies are directed to the search for new 
pharmacological approaches to allow, either alone or in combination with the 
cholinaesterase inhibitors, to obtain a better clinical response. Moreover, in recent 
years, increasing attention has been reserved to the formulation of innovative 
pharmaceutical systems, and to the investigation of administration routes, 
alternatives to the oral route, which serves to improve the performance of drugs 
already in use. Moreover, considering the key role of oxidative stress in the 
pathogenesis and progression of the disease, it would be deliverable to combine  the 
approved AD therapy with the treatment of the OS.  
Finally, during the past several years, we have witnessed enormous growth in 
scientific information regarding AD. To this point, however, little of this information 
has been translated into effective treatments. The future goal of the scientific 
research is to join together all the knowledges acquired. In fact, AD is a 
multifactorial disease and then must be addressed with a multidisciplinary strategy, 
uniting to drug discovery the development of new pharmaceutical systems capable to 
delivery the active molecules directly into Central Nervous System (CNS), 
increasing the therapeutic efficacy and at the same time reducing side effects.  
 
2. Intranasal drug delivery
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A 
 
 
 
2. INTRANASAL DRUG DELIVERY 
 
 
Though great progress have been achieved regarding our understanding of the 
pathogenic basis of neurological disease, there are only a small number of effective 
drugs for treating these diseases. Every day new potentially active molecules are 
synthesized but they are discarded for their toxicity or low bioavailability. In fact, the 
main limitation  for a drug active on the central nervous system (CNS) is precisely to 
carry it in the CNS, that as well known is overprotected by the blood-brain barrier 
(BBB) (Fig. 2.1) that segregates the brain interstitial fluid from the circulating blood. 
In particular, BBB histological morphology comprises two plasma membranes in 
series, separated by about 0.3 mm of endothelia cytosol [16]. This barrier ensures the 
interface between the cerebral capillaries and the brain tissue over a surface of 
interface of about 12 m
2
 [17]. The cells of the capillary endothelium are closely 
connected via intercellular connections; the tight junctions that act as zips closing the 
Fig. 2.1  Blood-Brain Barrier (BBB). (A) Diagram of a brain capillary in cross section and 
reconstructed views, showing endothelial tight junctions and the investment of the capillary by 
astrocytic end feet. (B) Electron micrograph of boxed area in (A), showing the appearance of 
tight junctions between neighboring endothelial cells (arrows). A  from Goldstein and Betz, 
1986; B from Peters et al., 1991. 
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inter-endothelial pores that normally exist in endothelial membranes, resulting in a 
greater transendothelial electric resistance (1500-2000 Ω.cm2) compared to that of 
other tissues like skin, bladder, colon, lungs (3-33 Ω.cm2) [18].  This makes the 
blood–brain barrier resistant to the free diffusion of molecules across the membrane 
and prevents most molecules from reaching the CSN from the blood stream. Less 
than 2% of all small-molecule drugs, and virtually no large-molecule drugs can cross 
the BBB. The obstacle imposed by those brain protective mechanisms has increased 
the interest in developing strategies to overcome them when brain drug exposure is 
required[19].  
Recently, much interest has been given to the exploitation of the nasal route for 
delivery of drugs, a lot of excellent reviews have been published examining in detail 
some particular aspects concerning to potential therapeutic applications of intranasal 
route of drug delivery [20-23]. Indeed, intranasal administration offers a variety of 
attractive options for local and systemic delivery of several drugs (Table 2.1). The 
nasal mucosa is richly vascularized and provides a series of unique attributes, all of 
which may help to maximize the patient’s safety, convenience and compliance. The 
nasal mucosa is, compared to other mucous membranes, easily accessible and 
provides a practical entrance portal for small and large molecules.  
 
Table 2.1 Advantages and limitations of intranasal administration [24] 
 
Nasal administration 
ADVANTAGES LIMITATIONS 
 
Drug degradation that is observed in the 
gastrointestinal tractis absent. 
 
 
Hepatic first pass metabolism is avoided. 
Rapid  drug  absorption  and  quick  onset 
achieved. 
 
The bioavailability of larger drug molecules can be 
improved by means of absorption enhancer or other 
approach. 
 
The  histological  toxicity of  absorption  
enhancers used  in nasal drug delivery system is 
not yet clearly established. 
 
Relatively inconvenient to patients when compared to 
oral delivery systems since there is a possibility of 
nasal irritation. 
 
Nasal cavity provides smaller absorption surface area 
when compared to GIT. 
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The nasal bioavailability for smaller drug molecules is 
good. Drugs that are orally not absorbed can be 
delivered to the systemic circulation by nasal drug 
delivery. 
 
Studies so far carried out indicate that the nasal 
route is an alternate  to  parenteral  route,  especially,  
for  protein  and peptide drugs. 
 
Convenient for the patients, especially for those on 
long term therapy, when compared with parenteral 
medication. 
 
Drugs possessing poor stability in g.i.t. fluids are 
given by nasal route. 
 
Polar  compounds exhibiting poor  oral  absorption 
may be particularly suited for this route of delivery. 
 
There is a risk of local side effects and irreversible 
damage of the cilia on the nasal mucosa, both from 
the substance and from constituents added to the 
dosage form. 
 
Certain surfactants used as chemical enhancers may 
disrupt and even dissolve membrane in high 
concentration. 
 
There could be a mechanical loss of the dosage form 
into the other parts of the respiratory tract like lungs 
because of the improper technique of administration. 
 
 
 
 
 
Intranasal administration offers a rapid onset of therapeutic effects, no first-pass 
effect, no gastrointestinal degradation or lung toxicity, non invasiveness, essentially 
painless application, and easy and ready use by patients. In addition, due to the 
olfactory region of nasal mucosa, drugs can be directly transported to the brain. It 
was realised  that the olfactory region is mayor site for entry viruses into the brain, to 
confirm this Shoshkes Reiss C. et al [25] inoculated on mice nasal epithelium, 
vesicular stomatitis virus; they reported as virus was transmitted along the olfactory 
nerve to the CNS within 12 h. Drug delivery into CNS through intranasal route has 
been reported [26-29] either in humans or animal models of Alzheimer’s disease [30-
31], brain tumours [32-33], epilepsy [34], pain [35] and sleep disorders [36]. Has 
been reported in literature that the drug uptake into the brain from the nasal mucosa 
mainly occurs via three different pathways (Fig. 2.2): 
 
 Systemic pathway by which part of the drug is absorbed into the systemic 
circulation subsequently reaches the brain by crossing the BBB; 
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 Olfactory pathway 
 Trigeminal neural pathway  
 
Drugs through olfactory and trigeminal pathways travels from the nasal cavity to 
cerebrospinal fluid (CSF) [37]. 
 
 
 
 
The drug can cross the olfactory path by one or a combination of mechanisms. These 
include transcellular or simple diffusion across the membrane, paracellular transport 
via movement between cells and transcytosis by vesicle carriers.  
 
 
Fig. 2.2 Brain drug uptake through different pathways after intranasal administration  
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2.1. Nasal anatomy and physiology  
 
The primary functions of the nasal cavity in humans and animals are breathing and 
olfaction. The structure and function of this cavity are related to the resonance of 
produced sounds, filtration of particles, mucociliary clearance, immunological 
activities and heating humidification of the inspired air before it reaches the lung 
[38]. In order to accomplish drug delivery to CNS, the drugs have to efficiently 
permeate across the nasal mucosa. For effective administration of drugs through the 
nasal rout, its anatomical and physiological features must be concomitantly taken 
into consideration in designing delivery system for the CNS. Therefore, an 
understanding of the anatomy and physiology of nasal mucosa is imperative [39]. 
The nasal cavity is subdivided along the centre into two halves by the nasal septum.  
 
Fig. 2.3 Section of the human nasal cavity, from SEER’s web based Training Module [SEER, 
2007, http://training.seer.cancer.gov/module_anatomy/images/illu_nose_nasal_cavities.jpg] 
 
The two cavities open to the facial side through the anterior nasal apertures and to the 
rhinopharynx via the posterior nasal apertures and each of two nasal cavities can be 
subdivided into different regions: nasal vestibule, inferior turbinate, middle turbinate, 
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superior turbinate, olfactory region, frontal sinus, sphenoidal sinus, and cribriform 
plate of ethmoid bone (Fig. 2.3). The total surface area of the nasal cavity in human 
adult is about 150 cm2 and total volume is about 15 ml. The olfactory region in men 
covers an area of about 10 cm2 and is positioned on superior turbinate on opposite 
septum. The respiratory region contains three nasal turbinates: superior, middle, and 
inferior which project from the lateral wall of each half of the nasal cavity. The 
presence of these turbinates creates a turbulent airflow through the nasal passages 
ensuring a better contact between the inhaled air and the mucosal surface. The nasal 
epithelial membrane provides a significant barrier to the free diffusion of substance 
across them [40-42]. The presence of tight junction between neighboring epithelial 
cells cancels the free diffusion of hydrophilic molecules through the epithelium via 
paracellular route. Tight junctions are located at the boundary between apical and 
boslateral domains in epithelial cell periphery. The structure and function of this 
cavity are related to the resonance of produced sounds, filtration of particles, 
mucociliary clearance, immunological activities and heating humidification of the 
inspired air before it reaches the lung [38]. 
 
 
 
2.1.1. Respiratory region 
 
The respiratory region is the largest, it is considered as the major site for drug 
absorption into systemic circulation having the highest degree of vascularity, it 
consists of an epithelium resting on a basement membrane and a lamina propria [43]. 
The anterior part of respiratory region covered with squamous epithelium, which 
changes to transitional epithelium and converts in the posterior part of the cavity to a 
pseudostratified columnar epithelium. The pseudostratified epithelium, also named 
the respiratory epithelium, consists of four dominated cell types; ciliated columnar 
cells, non-ciliated columnar cells, goblet cells and basal cells (Fig. 2.4). The basal 
cells are situated on the basal membrane and don’t extend to the apical epithelial 
surface, as do the other three cell types. It is also rich in dendritic cells important for 
local immune response (IgA). A total of 15-20 % of the respiratory cells covered by 
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layer of long cilia of size 2-4 μm. The cilia move in coordinated way to propel mucus 
across the epithelial surface towards the pharynx [41]. The respiratory cells are also 
covered by about 300 microvilli per cells. Mucus layer consists of low viscosity 
sollayer that surrounds the cilia and a more viscous gel layer forming a layer on the 
top of the sol layer and covering the tips of the cilia. The epithelial cells are closely  
 
 
connected on apical surface, surrounded by intercellular junction whose specialized 
sit and structural components are commonly known as junction complex [22, 40]. Its 
is innerved by trigeminal nerves, which enter the brain both through the pons and 
separately through the cribioform plate under the olfactory bulbs [44]. 
 
 
Fig. 2.4 The respiratory epithelium is covered by a mucus layer (gel and sol layer) and the 
cell types arising from the basement membrane are: ciliated and non-ciliated cells (with 
microvilli), goblet cell, and basal cell. Modified from Histology of the Respiratory System 
McGill Molson Medical Informatics Project (Dr Morales)  
http://alexandria.healthlibrary.ca 
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2.1.2. Olfactory region 
 
The olfactory region is situated between the nasal septum and the lateral walls of 
each of the two nasal cavities and just below the cribriform plate of the ethmoid bone 
separating the cranial cavity from nasal cavity. In men, the epithelium is restricted to 
a small area in the roof of the nasal cavity of a bout 10 cm2 as compared to an area 
of about 150 cm2 in dogs, which reflects the major importance of the sense of smell 
to the dog [40]. The olfactory epithelium is innerved by olfactory nerves (Fig. 2.5)  
which is responsible for the transport of drugs from nasal cavity to the CNS along the  
intraneuronal/extraneuronal olfactory pathway region provides a potential advantage  
 
where a drug may be exposed to neurons that may be facilitated it across into 
cerebro-spinal fluid when administered intranasally [38, 41]. Various studies in 
animal models have conformed that, at early time points after nasal administration, 
the concentration of cocaine in the brain was higher after nasal administration than 
after intravenous injection, thereby showing the existence pathway from nose to 
brain [45]. Fehm et al. reported a significant accumulation of insulin In cerebrospinal 
fluid after a single administration of 40 IU insulin, whereas no increase was seen in 
insulin plasma levels [46]. It should be stressed that the blood supply to the nasal 
Fig. 2.5 Diagram of the olfactory area showing the olfactory epithelium, bulb and 
tract. Modified from Adams et al. (1989). 
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mucosa is pertinent with regards to systemic drug delivery. The arterial blood supply 
to the nasal cavity is derived from both the external and internal carotid arteries. The 
terminal branch to the maxillary artery supplies the sphenopalatine artery, which in 
turn supplies the sphenopalatine artery, which in turn supplies the lateral and medial 
wall of the nasal chamber. The anterior and posterior ethmoid branches come from 
the ophthalmic artery, which is a branch of carotid artery. These vessels supply the 
anterior portion of the nose. The veins of the nasal cavity drain into the 
sphenopalatine foramen and then into sphenopalatine foramen pterygoid plexus [47]. 
 
 
 
2.1.3. Nasal secretion 
 
The epithelium in a clean, non-infected, non-allergic and non-irritated nose is 
covered by a mucus layer, which is secreted by goblet cells and serous glands in the 
nasal mucosa and sub-mucosa [38]. About 90-95% of mucus layer consists of water 
with electrolyte, serum protein, immunoglobulins and lipids; while 3% consists of 
mucin [48]. The mucus moved through the nose at an approximate rate of 5 to 6 
mm/min, so is renewed every 10 to 15 minutes. The nasal mucus performs a number 
of physiological functions; is including physically and enzymatically protection, 
water-holding capacity; permits efficient heat transfer and acts as adhesive and 
transports particulate matter towards the nasopharynx [49]. The average pH in the 
anterior of the nose is 6.40; while, the pH in the posterior of the nasal cavity is 6.27 
[50]. Generally, the normal pH of the nasal secretions in adult ranges from 5.5-6.5, 
whereas in infants and young children it ranges from 5.0- 6.7 [38]. A change in the 
pH of mucus can affect the ionization and thus increases or decreases the permeation 
of drug, depending on the nature of the drug. The effect of altering nasal pH on the 
absorption of certain drugs has been studied in animals and animal models. 
Morimoto et al. demonstrated in rat an enhanced absorption of vasopressin by a 
reduction in pH; it should be noted however that, this pH reduction caused an 
adverse effect on ciliary beat [51]. 
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2.2. Factors influencing the absorption of drugs across the nasal epithelium 
 
Drug delivery from the nose to the CNS can be achieved via olfactory 
neuroepithelium and can involve paracellular (inter cellular spaces and tight 
junction), transcellular (passive diffusion, active transport and transcytosis) and/or 
neuronal transport. The factors influencing nasal absorption are related to nasal 
physiology, the physico-chemical characteristics of the compound and the properties 
of specific drug formulation [52] (Fig. 2.6). 
 
 
 
Fig. 2.6 Factor influencing nasal absorption. The three main factors are: Anatomical and              
Physiological nasal characteristics, drug Physiochemical properties and the           
characteristics of the Formulations. 
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2.2.1. Physiological barrier 
 
The nasal mucociliary clearance system transports the mucus layer that covers the 
nasal epithelium towards the nasopharynx by ciliary beating. Its function is to protect 
the respiratory system from damage by inhaled particulate and substances. 
Impairment of nasal mucociliary clearance can result in diseases of the upper 
airways. One of the functions of the upper respiratory tract is to prevent noxious 
substances (allergens, bacteria, viruses & toxin) from reaching the lungs. Generally, 
when such materials adhere to, or dissolve in the mucus lining of the nasal cavity, 
they were transported towards the nasopharynx for eventual discharge into the 
gastrointestinal tract. Clearance of this mucus and the adsorbed/dissolved substances 
into the gastrointestinal tract is called the mucociliary clearance (MCC) [49]. Nasal 
clearance proceeds at average rate of about 5-6 mm/min [38]. With a beat of ~ 100 
stokes per min, the cilia transport the mucus with speed of 5 mm/min and 
formulations administered on the human respiratory epithelium has been found to be 
cleared from the nasal cavity with half-life of clearance of about 20 min. Nasal 
mucociliary clearance also has implications for nasal drug absorption. Drugs are 
cleared rapidly from the nasal cavity after intranasal administration, so it is important 
a fast systemic drug absorption. Several strategies are discussed to increase the 
residence time of drug formulations in the nasal cavity, resulting in improved nasal 
drug absorption [53]. Indeed, reducing the mucociliary clearances increases the time 
of contact between a drug and the mucus membrane and subsequently enhances drug 
permeation; vice versa increasing mucociliary clearances decreases drug permeation. 
Therefore, strategies to increase the nasal bioavailability of drugs that are poorly 
absorbed from the nasal mucosal can be aimed either at increasing the nasal 
membrane permeability or by decreasing the mucociliary clearance rate [54]. Zaki 
N.M. et al. developed a mucoadhesive in situ gel reducing nasal mucociliary 
clearance and improving the bioavailability of the antiemetic drug, metoclopramide 
hydrochloride. Definitively, the prolong contact time has been attributed to the 
rheological properties of the formulation, which reduce or delay its clearance from 
the mucosa and may result in specific interactions of the polymer in the gel with 
mucus components [55]. A large number of methods have been used to assess 
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mucociliary function, these methods study the mucociliary system whole (in-vivo) or 
as its separate components (in-vitro or ex-vivo) i.e., the ciliary activity and mucus 
layer [54].  
Another important barrier to the drug nasal absorption is its enzymatic metabolism; 
in fact, though drugs administered nasally avoid first pass hepatic metabolism, there 
is a wide range of metabolic enzymes located in the nasal mucosa that may limit the 
bioavailability of some drugs, especially those containing peptides or proteins [56]. 
Nasal mucosa acts as an enzymatic barrier to the delivery of drug; indeed, has been 
reported the presence in substantial amounts in the nasal cavity of a large number of 
enzymes [57], which include: 
 
 Cytochrome P-450: it was apparent that nasal tissue contained high levels of 
P-450 isozymes (10 forms) that very actively catalyzed the oxidation of 
certain substrates. Thus, the turnover rate (nanomoles of substrate per 
picomoles of P-450 per minute) for nasal microsomal, P-450-dependent 
aniline hydroxylation was six time higher than for liver Cytocrome P-450.  
 Aldehyde Dehydrogenases: is a polymorphic enzyme responsible for the 
oxidation of aldehydes to carboxylic acids. The formaldehyde 
dehydrogenases are most abundant in olfactory mucosa, while acetaldehyde 
dehydrogenase activity is most abundant in the nasal respiratory tissue. 
Another interesting difference in the location of these enzymes is the 
presence of formaldehyde dehydrogenase in olfactory sensory cells, while 
aldehyde dehydrogenase is absent from those cells. 
 15-lipoxygenase: is an enzyme that catalyzes the oxidation of arachidonic 
acid to yield 15-hydroperoxyarachidonate (15-HPETE) which is rapidly 
converted to 15-hydroxy-5,8,11,13-eicosatetraenoate (15-HETE). The 15-
hydroperoxides are preferentially formed in neutrophils and lymphocytes. It 
was seen that this enzyme is more active in nasal epithelial cells than 
bronchial cells. 
 Alcohol Dehydrogenases: are a group of dehydrogenase enzymes that 
facilitate the interconversion between alcohols and aldehydes or ketones with 
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the reduction of nicotinamide adenine dinucleotide (NAD
+
 to NADH). 
CH3CH2OH + NAD
+
 → CH3CHO + NADH + H
+
. 
 Carboxylesterases: is an enzyme that catalyzes the chemical reaction a 
carboxylic ester + H2O an alcohol + a carboxylate. Carboxylesterase 
activities in the nasal cavity are among the highest of any activities found 
there, but little is known about the biochemistry of the nasal forms. 
 Epoxide Hydrolases: also known as epoxide hydratase) functions in 
detoxication during drug metabolism. It converts epoxides to trans-
dihydrodiols, which can be conjugated and excreted from the body. 
Metabolizes especially  styrene oxide and benzo(a)pyrene-4,5-oxide. High 
levels of hydrolase activity with these substrates have been reported in rat 
nasal tissue.Safrole oxide hydrolase activity was reported to be higher in 
human nasal tissue than in rat nasal tissue. 
 UDP-Glucuronyl Trasferase: is a glycosyltransferase that catalyzes addition 
of the glycosyl group from a UTP-sugar to a small hydrophobic molecule. 
This reaction is known as glucuronidation reaction. Activities of this UDP-
glucuronyl transferase have been observed in the nasal tissues of the rat and 
of the dog. With 1 -naphthol as the substrate, Gervasi and co-workers could 
not detect glucuronidation in human nasal respiratory tissue homogenates. 
 Glutathione S-Transferase(GTS): Are an enzyme family that catalyse the 
conjugation of reduced glutathione — via a sulfhydryl group — to 
electrophilic centers on a wide variety of substrates. This activity detoxifies 
endogenous compounds such as peroxidised lipids, as well as breakdown of 
xenobiotics. GSTs may also bind toxins and function as transport proteins, 
and, therefore, an early term for GSTs was “ligandin”. The mammalian GST 
super-family consists of cytosolic dimeric isoenzymes of 45–55 kDa size that 
have been assigned to at least six classes: Alpha, Mu, Pi, Theta, Zeta and 
Omega. Are present in high concentrations in both respiratory and olfactory 
epithelia. Glutathione S-transferase activity has been demonstrated in human 
nasal respiratory tissue by using l-chloro-2,4-dinitrobenzene as the substrate. 
The activity in human nasal tissuewas greater than that in rat nasal tissue. 
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 Rhodanese: is a mitochondrial enzyme that detoxifies cyanide (CN-) by 
converting it to thiocyanate (SCN
-
). This reaction is important for the 
decontamination of cyanide, since the thiocyanate formed is relatively 
harmless. The use of thiosulfate solution as an antidote for cyanide poisoning 
is based on the activation of this enzymatic cycle. The activity of this enzyme 
in the rat, cow and human nasal tissues is quite high, and its kinetics in both 
the rat and human suggests that an isozyme different from that in the liver 
may be present in the nasal cavity of both species. 
 
Particularly, the nasal cytochrom P450-dependent monooxygenase system has been 
implicated in nasal metabolism of nasal decongestants, alcohol, nicotine and cocaine 
[58]. Histochemical, immunohistochemical, and biochemical localization of many 
nasal xenobiotic metabolizing enzymes indicate that these enzymes are often highly 
localized in specific tissues, cells, and portions of cells. Finally, the nasal 
cytochromes P-450, in contrast to those of the liver, are relatively resistant to 
induction but are easily inhibited. On the basis of this, the nasal route is still 
considered to be superior to the oral route. Various approaches have been used to 
overcome these degradations. These include the use of protease and peptidase 
inhibitors such as bacitracin, amastatin, boroleucin and puromycin, which have been 
reported to improve the absorption of many drugs [59].  
 
 
2.2.2. Physicochemical characteristics of the drug 
 
The physiochemical characteristics of the administered drug, which can influence 
nasal absorption, include molecular weight, solubility, dissolution rate, charge, 
partition coefficient, pKa, particle size and the presence of polymorphism [47]. 
Molecular weight (MW), size and lipophilicity or hydrophilicity play a key role in 
nasal drug permeation. Generally, the permeation of drugs less than 300 Da is not 
significantly influenced by the physiochemical properties of the drug, they can 
permeate through aqueous channels of the membrane (paracellular mechanism). On 
the contrary, for a large number of therapeutic agents including peptides and 
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proteins, which have MW largest than 1 KDa, bioavailability is low and can be 
directly predicted from knowledge of MW. In general, the bioavailability of these 
large molecules ranges from 0.5% to 5% [60], but can be increased formulating these 
molecule in combination with enhancer substances, which open the tight junctions.  
Other factors also can affect transport pathways are the pH and the osmolarity of the 
formulation; in fact, several authors have reported how modifying these two 
parameters in the formulation can increase the drug bioavailability [61]. Drug 
lipophilicity is one of the most important physiochemical characteristic that a drug 
has to posses to improve nasal permeability; in fact, though the nasal mucosa was 
found to have some hydrophilic characteristics, it appears that this mucosa are 
primarily lipophilic in nature and the lipid domain plays an important role in the 
barrier function of these membranes [62]. Generally, the permeation of the 
compound through nasal mucosa increases on increasing the lipophilicity. It should 
be noted however, that the lipophilicity is in contrast with the drug solubility in the 
aqueous medium. Whereas water represents the 95% of the nasal secretions, drug 
solubility is probably the most crucial factor in determining absorption through nasal 
mucosa. Poorly aqueous soluble drugs may require high doses, making this 
administration route impractical. The problem can be overcome by enhancing drug 
solubility using various techniques. Finally, tied to solubility there is the dissolution 
rate that is equally important; especially for particulate nasal products, administered 
as either powder inhalation or in the form of suspensions, where the dissolution rate 
becomes extremely important; in fact, particles deposited in the nostrils need to be 
dissolved prior to absorption, otherwise drug is moved away by mucociliary 
clearance without being absorbed.  
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2.3. Strategy to improve intranasal drug absorption 
 
The poor nasal bioavailability of many substances (in particular, peptide and protein 
drugs) can be substantially improved by the use of absorption enhancer. The 
acceptability of these enhancer is not only dependent on their promoting effect but 
also on their safety profile for systemic and local adverse effects. Nasal drug 
formulations must not alter the histology and physiology of he nose in the sense that 
the mucosa must retain its functionality as a barrier toward external substances and 
microorganism. The histological toxicity refers to the alteration of mucosa, including 
membrane protein removal, cell loss, excessive mucus discharged , cilotoxicity, and 
disturbing of the normal enzymatic balance. In literature there is a lot of studies that 
reported the enhancing absorption  effect of several substances [63-67]. Generally 
these substances act as enzyme inhibitors to overcome the enzymatic barrier and 
permeation enhancer to overcome the physical barrier opening the tight junctions, 
alterating the properties of mucus layer, chelating Ca
++
 ions in the cell membranes, 
increasing membrane fluidity. It is possible also a combination of effects, Sayani and 
Chien listed several enzyme inhibitors the stabilized peptides and at same time 
enhanced permeation [68]. A classification of the major enhancer molecule used was 
reported by Ramesh [69]: 
 
 Surfactants (Polyozyethylene-9-lauryl ether (Laureth-9), Saponin): Sajadi 
Tabassi SA reported a high reduction of the blood glucose levels following the 
nasal instillation of solutions containing insulin and Acanthophyllum total 
saponin [70]. The enhancing effect seems to be tied to a reduction in water 
surface tension; it should be noted however that this effect is also toxic; in fact, 
caused complete haemolysis of human red blood cells at a concentration of 250 
µg/ml. 
 
 Bile salts (Trihydroxy salts (glycol- and taurocholate), Fusidic acid derivatives 
(STDHF)): Sodium deoxycholate a typical bile salt was used in concentration of 
1% to improve the bioavailability of dopamine in beagle dogs via nasal route, a 
20% increase in bioavailability of dopamine has been obtained [71]. Several 
other studies indicate that bile salts can prove to be good optimizers in nasal drug 
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products. Fusidate derivates show similar physical and chemical properties to the 
bile salts, and so have been suggested to enhance absorption in a similar manner. 
Deurloo MJ described an excellent nasal absorption of insulin due to the 
enhancing effect of Sodium taurodihydrofusidate (STDHF); particularly, the 
fusidate derivative at 1% (w/v) enhanced nasal insulin bioavailability from 0.9 to 
5.2% and from 0.3 to 18.0% in rabbits and rats, respectively. Emerged so that 
STDHF is a potent enhancer of nasal insulin absorption, probably both by 
facilitating insulin transport through the nasal mucosa and possibly also by 
inhibiting enzymatic degradation [72].To quantify the toxicity of these 
substances, Zezhi Shao et al. investigated in nasal rat the protein and enzyme 
release following the administration of four bile salts, one fusidate derivative[73]. 
Deoxycholate (NaDC) was found to possess the maximum protein solubilizing 
activity, followed by taurodihydrofusidate (STDHF), cholate, glycocholate 
(NaGC), and taurocholate (NaTC) in a descending order. 
 
 Chelators (Salicylates, Ethylenediaminetetraacetic acid (EDTA)): It was seen 
that the mechanism of action of ethylene-diamine-tetraacetic acid (EDTA) 
includes depletion of Ca2+ from tight junctional areas, thus allowing the 
junctions to open. In fact, the integrity of the tight junctions, which may be seen 
as barriers to the paracellular diffusion of molecules, is dependent on 
extracellular Ca2+.   The effect of EDTA on nasal absorption was studies, results 
showed a promoting effect of EDTA on absorption of fluorescein iosthiocyanate-
dextrans with various molecular weights after nasal administration to [74].  
 
 Fatty acid salts (Oleic acid, Caprylate (C8), Caprate (C10), Laurate (C12)), 
Phospholipids (Lysophosphatidylcholine (lyso-PC), Didecanoyl – PC): 
Saturated (for example, lauric, myristic and capric acid) and unsaturated fatty 
acids (for example, oleic acid, linoleic acid and linolenic acid) have penetration 
enhancing property of their own and they have been studied since a long time. 
Fatty acid esters such as ethyl or methyl esters of lauric, myristic and oleic acid 
have also been employed as the oil phase of emulsion. Tugrul T. Kararli 
evaluated the enhancing effect of the oleic acid/monolein emulsion on the nasal 
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absorption of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L-leucinamide of 
(2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane, a renin 
inhibitor; in comparison with a control PEG 400 solution. Results highlighted 
that the percent absolute bioavailability of the compound was enhanced from 3–
6% (PEG 400 solution) to 15–27% when the emulsion formulations were used 
[75]. The phospholipid didecanoylphosphatidylcholine (DDPC) has shown 
absorption-enhancing properties in the nasal absorption of insulin and growth 
hormone. Agerholm et al. suggested that the major transport route of human 
growth hormone after intranasal administration to rabbits in vivo formulated with 
DDPC was transcellular through lethally damaged ciliated cells [76]. 
 
 Cyclodextrins (α, ß, and γ- cyclodextrins and their derivatives): Cyclodextrin 
(CDs) are cyclic oligosaccharides shoeing a polar outer surface and an apolar 
interior cavity able to include lipophilic guest molecules. CDs can enhance 
lipophilic drug absorption by the solubilisation and protection against 
physiochemical  and enzymatic degradation [77]. Thus CDs are also able to 
enhance hydrophilic drug absorption by the extraction of specific lipids from 
biological membranes, leading to an increase in membrane permeability and 
fluidity [78]. The extent of protection and absorption enhancement seems to 
depend CDs strongly on the nature of the drug used as well as on the CD used. 
For example, in vivo studies in rats have demonstrated that the addition of 5% α-
CD to nasal preparation of insulin resulted in an absolute bioavailability of 
approximately 30%; on the contrary, β- and γ-CD did not effect insulin 
absorption. However, dimethyl-beta-cyclodextrin (DMβ-CD) gave rise to a large 
increase in insulin absorption, with a bioavailability of 100%[79]. Based on 
toxicological studies of the local effects of cyclodextrins on the nasal mucosa 
DMβ-CD and randomly methylated beta-cyclodextrin are considered safe nasal 
absorption enhancers. Their effects were quite similar to controls (physiological 
saline), but smaller than those of the preservative benzalkonium chloride in 
histological and ciliary beat frequency studies. 
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2.4. Micro/nanocarriers for nasal drug delivery  
 
The use of pharmaceutical micro/nanocarriers (micro/nanoparticles, micro/nano 
emulsion, micelles and liposomes)  to enhance the in vivo efficiency of many drugs 
well established itself over the past decade both in pharmaceutical research and 
clinical setting. These systems can include, besides the drug, enzymatic inhibitors, 
nasal absorption enhancers or/and mucoadhesive polymers in order to improve the 
stability, membrane penetration and retention time in nasal cavity.  
 
 
 
2.4.1. Microspheres 
 
Microsphere technology is one of the specialized carriers becoming extremely 
popular for designing nasal products, as it may provide prolonged and intimate 
contact with the nasal mucosa and thus increasing absorption and bioavailability 
[80]. Normally microspheres, due to moisture uptake, dehydrates the nasal mucosa. 
This result in reversible shrinkage of the cells, providing a temporary physical 
separation of the tight junctions that increases the absorption of the drugs, also of 
high molecular weight molecules such as insulin. As mentioned before, one of the 
most important anatomical region of the nose  for the drug absorption is the 
respiratory region, which is richly vascularised and contains three nasal turbinates, 
the deposition of the particles in this region depend on the microsystems size. 
Classically, larger particles including droplets (>10 µm), are deposited in the nasal 
cavity after inhalation; the larger the particles, the more anterior the deposition. For 
smaller particles the site of deposition depends on the velocity at which the particles 
are inhaled and the turbulence in the air flow, however the particles of size smaller 
than 1 µm are not normally deposited in the nasal cavity but travel down to the 
trachea to reach the lung. The ideal microsphere particle size requirement for nasal 
delivery should range from 10 to 50 µm as smaller particles than this will enter the 
lungs. However, studies have reported that a significant portion of small particles are 
also deposited in the nose [81]. The capacity of removal for the upper respiratory 
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tract is 100% for the particles with size larger than 10 µm, and approximately 80% 
for the particles of 5 µm. Clearance capacity drops progressively with further 
reduction in size and approaches zero for particles at 1-2 µm. Studies have also 
reported that 4 µm is the sufficient size for the nasal delivery [82]. 
The rationale behind the use of a microsphere system is the mucoadhesion; in fact, 
the administration of bioadhesive microsystems (in the powder form) with good 
mucoadhesive properties would permit such microspheres to swell in contact with 
the liquid present on nasal mucosa to form a gel and control the rate of clearance 
from the nasal cavity, thereby allowing poorly absorbed active molecules a longer 
time on the absorptive surface. It has been shown that microspheres formed by 
bioadhesive materials are retained in the nasal cavity with half-life clearance of 3h or 
longer, compared with 15-20 minutes for usual formulations [83]. Numerous 
examples of microparticulate systems, optimized for nasal administration, produced 
using different bioadhesive materials have been evaluated in-vivo as nasal drug 
delivery systems. Intranasal alginate mucoadhesive microspheres of carvedilol, 
prepared by emulsification cross-linking, showed an availability of 68% compared to 
intravenous administration of the drug [84]. Another material used by Illum et al, 
was degradable starch microspheres, was seen that those microparticles increase 
absorption of human growth hormone and desmopressin [85,86]. Special attention 
should be reserved to the chitosans, these are biodegradable high weight cationic 
polysaccharides, that in the last decade have been intensively studied as excipients 
for drug delivery especially for nasal formulation, due to their mucoadhesive 
properties and not only. In fact, their mechanism of nasal transport enhancement is a 
combination of bioadhesion and transient  opening of the tight junction in the 
membranes. The cell-binding activity of chitosans is related to electrostatic 
interactions between cell surfaces charged negatively and the cationic polyelectrolyte 
structure. In addition, chitosans have no arresting effect on the mucociliary  
clearance, and they do not cause significant changes in nasal mucosa histology [87]. 
Medium molecular  weight chitosans are able to enhance the nasal absorption in 
animals and in human volunteers of polypeptides and other polar drugs, such as 
insulin, salmon calcitonin, and morphine metabolites(un po di biblio). In relation of 
these consideration, the combination of a bioadhesive polymers and permeation 
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relatively nontoxic enhancers can be of promising potential for developing a 
excellent nasal formulation.  
 
 
 
2.4.2. Nanoparticles 
 
Nanoparticles may offer an improvement to nose-to-brain drug delivery since they 
are able to protect the encapsulated drug from biological and/or chemical 
degradation. Nanoparticles are solid colloidal particles ranging in size from 10nm to 
1μm.  They are made of macromolecular material which can be of synthetic or 
natural origin. On the basis of the process used for their preparation, two different 
types of nanoparticles can be obtained (Fig. 2.7), namely nanospheres in which a 
drugs is dispersed in the matrix structure and nanocapsules that present a membrane-
wall structure with an oily core containing the drug.  
 
 
Nanoparticulate drug delivery systems can improve significantly the transport of 
drugs across the nasal mucosa as compared to drugs solutions. The strategy of 
applying drugs that are encapsulated into nanoparticles to the olfactory epithelium 
could potentially improve the direct CNS delivery of drugs. If drugs could reach the 
CNS in sufficient quantity by this route, due to the nanosystem, it could generate 
Fig.  2.7  Difference between (A) nanospheres (matrix structure) and (B) nanocapsules 
(membrane-wall structure with an oil core) 
A B 
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interest in previously abandoned drug compounds (foe example Tacrine) and enable 
an entirely novel approach to CNS drug delivery [88]. Literature on the potential of 
the nanoparticles as efficient nasal drug delivery system remain still contrasting. In 
fact, there are examples in the literature where it has been shown that nanoparticles 
are not as efficient as alternative solution formulations [89]. Although there are other 
studies that highlighted the enhancing effect of the nanoparticles; for example Seju U 
et al. evaluated the CNS absorption of olanzapine as a result of intranasal 
administration of olanzapine-loaded PLGA nanoparticles, they found that in vivo 
olanzapine was 6.35 and 10.86 times higher uptake of intranasally delivered 
nanoparticles than olanzapine solution delivered through intravenous and intranasal 
route, respectively. Highlighted a probable direct transport to the brain after 
intranasal administration of nanoparticles [90]. Therefore is not yet clear  from the 
published literature whether these nanoparticles are improving delivery by 
transporting an encapsulated drug across the membrane barrier or merely keeping the 
system longer in the nasal cavity or protecting the drug from enzymatic degradation. 
Another explanation could be the uptake of the entire nanoparticles in the neurons, 
present in the olfactory region or in the trigeminal nerve, due to an endocytosis 
process. Have been studied various endocytic pathways that are very well provided 
by Alpesh Mistry et al [88]; generally, nanoparticles may be taken into the neurones 
and supporting cells by a number of endocytic mechanisms. However, nanoparticles 
larger than 100 nm are thought to have a restricted access to the brain via the 
intraaxonal route because their diameter increasingly exceeds that of the axons. 
 
 
 
2.4.3. Liposomes 
 
Liposomes consist of one or more concentric lipid bilayers, which enclose one or 
more internal aqueous volume. The presence of two different environments in the 
carrier, the aqueous and the phospholipid membrane, makes liposomes a  versatile 
nanocarrier for a broad of hydrophilic, amphipatic and hydrophobic small and macro 
molecules. Moreover, liposomes present good compatibility, low toxicity, lack of 
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immune system activation, and targeted delivery of bioactive compounds to the site 
of actions.  Liposmes are classified according their structural parameters [91] (Fig. 
2.8) or based on their method of preparation [92]. In the Table 2.2 there is an 
accurate classification based on structural parameters and on the methods of 
preparation. Besides being able to prepare liposomes with different methods that 
allow to obtain very different physical structures, it is also possible to vary the lipid 
composition and surface properties, thus allowing a large amount of control over the 
fate of their content. In addition, in liposome bilayer or in the aqueous phase is 
possible to add substances like tocopherol (see experimental section), which permit 
to obtain liposomes that in addition to improving drug absorption, they can provide 
an antioxidant effect, very useful in the treatment of neurodegenerative disease. For 
these reasons, they have been explored very widely as delivery vehicles. 
The basic aspects and the advantages to use liposome like drug delivery system can 
be summarized in: (1) protection -  the active materials are protected by virtue of the 
membrane  barrier function and  by the possibility  to coencapsulate protective agents 
 
 
Table  2.2  Liposome classification 
  
Liposome Classification 
Based on Structural Parameters Abbreviation Based on Method of Preparation Abbreviation 
Multilamellar Large Vesicles >0.5μm MLV 
Single or Oligolamellar Vesicles made 
by Reverse-phase Evaporation 
REV 
Oligolamellar Vesicles 0.1-1μm OLV 
Multilamellar Vesicles made by 
Reverse-phase Evaporation 
MLV-REV 
Unilamellar Vesicles (all size range) UV Stable Plurilamellar Vesicles SPLV 
Small Unilamellar Vesicles 20-100nm SUV Frozen and Thawed MLV FAT-MLV 
Medium sized Unilammelar Vesicles MUV Vesicles prepared by Extrusion methods VET 
Large Unilamellar Vesicles >100nm LUV Vesicles prepared by French press FPV 
Giant Unilamellar Vesicles >1μm GUV Vesicles prepared by fusion FUV 
Multivesicular Vesicles >1μm MVV Dehydration-Rehydration Vesicles DRV 
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Fig. 2.8  Liposome classification based on structural parameters.   (A) Multilamellar Large 
Vesicles >0.5μm (MLV), (B) Large Unilamellar Vesicles >100nm (LUV) and (C) Small 
Unilamellar Vesicles 20-100nm (SUV). 
 
 
such as antioxidant molecules; (2) sustained release – such release is dependent on 
the ability to vary the permeability characteristics of the membrane by control of 
bylayer composition and lamellarity; (3) controlled release – drug release is enabled 
by exploiting lipid phase transitions in respose to external triggers such as changes in 
temperature or pH; (4) targeted delivery – such delivery can be achieved by relying 
on natural attributes such as liposome size and surface charge to effect passive 
delivery to body organs or by incorporating antibody or other ligands to aid delivery 
to specific cell types. At the same time drugs can be directed away from vulnerable 
or unintended targets; (5) internalization – this occurs by encouraging cellular uptake 
via endocytosis or fusion mechanism, for example, to delivery genetic materials into 
cells.  All these features make liposomes excellent candidates for nasal drug delivery; 
in fact, in addition to these, was also seen that liposomes are able to decrease 
mucociliary clearance due to their surface viscosity and exchange phospolipids with 
the membrane and opening ‘‘new pores’’ in the paracellular tight junctions; resulting 
in an increase in permeability. Moreover, promising results were been shown not 
only with small molecules but also with large molecules. Numerous examples are 
reported in the literature, which show the superiority and the convenience of the use 
of liposomes with respect to the simple solution of the drug; for example Maitani, Y 
et al [93] reported that insulin presented a better nasal permeability through nasal 
A 
B 
C 
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mucosa of rabbit, when it was encapsulated in the liposomes compared to insulin 
solution.  Jain, A. K. et al estimated, again using insulin as a model drug, the 
mucoadhesive properties of liposomes. They reported that liposomes shown to be 
marginally effective after nasal administration compared to ocular route although 
better therapeutic profile as the hypoglycaemic effects were prolonged until 72 h 
[94]. In another study Alsarra, I. A. et al highlighted that acyclovir mucoadhesive 
liposomes showed good permeability characteristics with enhanced nasal penetration 
of acyclovir in comparison to free drug suspended in gel. This result  could be 
attributed to both encapsulation in liposomes and incorporation nasal mucoadhesive 
gel. Nasal bioavailability of acyclovir was 60.72% calculated relative to the serum 
acyclovir levels over a period of 8h after intravenous injection of acyclovir [95]. 
Law, S. L. et al studied indeed the effect of liposomes charges on nasal absorption of 
calcitonin. They reported that positively charged liposomes had a better 
bioavailability than negative and especially than calcitonin solution. The significant 
bioavailability enhancement of the positively charged liposomes may be explain with  
interaction of positively charged liposomes with the negatively charged mucosal 
surface. This retention allowed an increase in the residence time of calcitonin and 
thus increased  bioavailability [96]. Very important is the opportunity using 
liposomes, to improve nasal drug delivery to CNS, various studied were done and all 
confirmed this ability. Arumugam, K. and his collaborators evaluated this ability, 
encapsulating rivastigmine in liposomes, an acetylcholinesterase inhibitor used in 
Alzheimer’s disease; this drug can be rapidly and completely absorbed after oral 
administration but is extensively metabolized by hepatic metabolism and by 
cholinesterase-mediated hydrolysis. They compared intranasal liposome with the oral 
free drug and found that liposomal formulation can provide ten times higher Cmax, 
higher systemic AUC, and higher concentration in the brain compared to oral 
administration. The higher rivastigmine brain concentration, following the intranasal 
liposome administration  might also be due to direct transfer of the drug or vesicles 
system from nasal mucosa to the brain via the olfactory route [97]. Non only small 
molecule but also protein can be encapsulated in liposomes and delivered to the 
brain, in an in vivo study Migliore, M. et al. evaluated the effectiveness of cationic 
liposomes for intranasal administration of proteins to the brain. Was encapsulated in 
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liposomes as protein model, ovalbumin (OVAL) marked with Alexa 488, and 
delivery was assessed by fluorescence microscopy. By 6 and 24h after 
administration, Alexa 488-OVAL deposits were widely distributed throughout brain, 
with apparent cellular uptake in midbrain by 6h after administration[98].  
 
 
 
 
2.4.4. Nasal inserts 
 
Nasal inserts are solid formulations that can be administered in the posterior of the 
nasal cavity [99,100] where they can be transformed rapidly into gels, thus avoiding 
the foreign body sensation. With respect to powders, for which precision of dosage is 
difficult to achieve, these new nasal systems are able to deliver an exact dose of drug 
into the nasal cavity. Owing to CH mucoadhesive properties, nasal inserts based on 
this polymer can adhere to the mucosa and prevent rapid clearance of the drug, thus 
increasing its residence time. Moreover, good control of drug release can be achieved 
through the crosslinked CH’s ability to form a gelled network in which the drug can 
diffuse. Finally, there is no need to remove the inserts mechanically from the nasal 
cavity because, after gel formation, they can be easily eliminated towards the 
nasopharynx by the mucociliary clearance. As nasal inserts are generally obtained by 
freeze-drying, which consists of sublimation of the frozen water yielding the 
formation of pores or channels in the polymer, they are characterized by a sponge-
like structure. The spongelike structure of nasal inserts is extremely important to 
ensure rapid rehydration and gelation at the administration site. Several works have 
reported the use of nasal inserts based on a well-known mucoadhesive gelling 
polymer such as hydroxypropyl methylcellulose [101-103]. Bertram and Bodmeier 
reported the formulation of nasal inserts [104] based on different polymers 
comprising CH glutamate. They found that the type of polymer chosen for insert 
preparation influences the mechanical properties of the inserts, their water uptake 
behaviour and bioadhesion potential and their ability to control drug release. In vitro 
studies revealed that CH is able to form a thin film on mucosal substrates 
(agar/mucin gel), owing to its opposite charge to mucin and agar, but it is less 
efficient at prolonging the contact time with the mucosa with respect to carrageenan, 
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Carbopol and other negatively charged polymers. The authors suggest that the good 
bioadhesion ability of these polymers is related to a good balance between available 
hydrogen bonding sites and an open expanded conformation. In a recent work, Luppi 
et al. [105] investigated the use of nasal inserts based on CH/hyaluronate complexes 
for peptide and protein delivery. CH/hyaluronate polyelectrolyte complexes were 
obtained in different preparative conditions and used for the preparation of 
lyophilized cone-like shaped inserts loaded with vancomycin or insulin. Drug release 
from in situ gelling systems is a complex phenomenon of water uptake, polymer 
chain relaxation, swelling, drug--polymer interactions, drug dissolution and diffusion 
through the rehydrated insert. The results indicate that the selection of suitable 
conditions for preparation of the complexes allows modulation of insert functional 
properties. Moreover, the water uptake ability of the different complexes can be 
influenced by the presence of insulin or vancomycin in nasal inserts, owing to the 
possibility of ionic interactions between drugs and polyelectrolyte complexes. On the 
contrary, insulin and vancomycin release from the gelled inserts seemed to be 
affected by the molecular mass of the drug but not by the presence of drug--complex 
interactions. In another work, Luppi [106] described the use of CH/pectin 
polyelectrolyte complex for the formulation of  chlorpromazine-loaded nasal inserts. 
The results show that higher amounts of pectin in the complexes, with respect to 
higher amounts of CH, produced a more evident porous structure of the nasal inserts, 
improving water uptake ability and mucoadhesion capacity. Finally, the presence of 
increasing amounts of pectin allows interaction with chlorpromazine hydrochloride, 
inducing the formation of less hydratable inserts, thus prolonging drug release and 
permeation. These investigations contribute to verifying the formation of 
polyelectrolyte complexes between CH and anionic polysaccharides (hyaluronic acid 
and pectin) at pH values in the vicinity of the pKa interval of the two counterions and 
to confirming their potential use for nasal drug delivery. 
 
 
 
 
  
 
 
 
 
EXPERIMENTAL SECTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Removal of the Nasal Mucosa of Sheep (Dr. G. Corace, July 2009, Bologna)
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3. ALBUMIN NANOPARTICLES CARRYING CYCLODEXTRINS FOR NASAL 
DELIVERY OF THE ANTI-ALZHEIMER DRUG TACRINE 
 
 
 
Fig.  3.1 Graphical Abstract. SEM image of freeze-dried Nanoparticles obtained, on the 
top left there is an Albumin nanoparticle carrying pure drug, on the top right there is an 
Albumin nanoparticle carrying pure drug and β-cyclodextrin 
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3.1. Introduction 
 
Tacrine (1,2,3,4-tetrahydro-9-aminoacridine monohydrochloride) (THA), a potent, 
centrally active, reversible cholinesterase inhibitor, was the first drug approved by 
the United States Food and Drug Administration (FDA) in 1993 for treating the 
symptoms of mild to moderate Alzheimer disease [107]. THA is available in the 
market as oral capsule dosage forms. Despite the favourable aqueous solubility, 
peroral administration of THA is associated with low bioavailability due to hepatic 
first-pass effect, short elimination half-life, gastrointestinal side effect and reversible 
dose-dependent hepatotoxicity, the major reasons for its withdrawal [108]. Hence the 
search for alternative routes of THA delivery such as transdermal [109,110] or, more 
recently, nasal route that deserved attention for rapid drug delivery to the central 
nervous system (CNS) [111]. 
Advantages of intranasal administration include a large surface area for drug 
absorption, rapid achievement of target drug levels and avoidance of first-pass 
metabolism [112]. Intranasal drug delivery systems should be designed to provide a 
controlled release and a complete absorption of drug at the mucosal site. In this view, 
hydrogel based systems and mucoadhesive excipients have been used to modulate 
drug release and prevent the rapid clearance of the drug formulation from the nasal 
cavity [113]. Among the various studied nasal formulations, nanoparticles have been 
found to improve drug transport across the mucosa due to the small particle size and 
the large total surface area favouring drug transfer from the formulation into the 
surrounding mucosa [114,115]. In the literature some studies describing the THA 
delivery in the CNS using intravenous administration of nanoparticles are reported. 
In particular, chitosan or poly(butylcyanoacrylate) nanoparticles have been evaluated 
after intravenous injection [116,117]. However, only few studies have been focused 
on THA delivery by nasal administration of nanosystems. Jogani and coauthors 
reported a study concerning the use of mucoadhesive microemulsion for targeting 
THA to the brain after intranasal administration in mice [118]. Their results suggest a 
possible role of intranasal THA delivery in treating Alzheimer's patients. 
The goal of this work was to prepare and evaluate a new intranasal formulation of 
THA based on albumin nanoparticles. In a previous study, we prepared thermally 
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cross-linked bovine serum albumin nanoparticles showing good mucoadhesion 
properties, useful to prolong drug absorption from the applied formulation [119]. 
Moreover, by virtue of its ability to interact with a wide variety of drugs, albumin 
was found an interesting material for loading the active ingredient in the delivery 
system. Finally, the three-dimensional network of cross-linked albumin was found 
useful to control drug release.  
In this study we tested bovine serum albumin nanoparticles carrying -cyclodextrin 
and some of its hydrophilic derivatives in order to assess if and how the presence of 
these cyclic oligosaccharides can modulate drug release, permeation through nasal 
mucosa and mucoadhesion. In fact, it was recently demonstrated that in addition to 
improve drug solubility, cyclodextrins added to intranasal formulation can improve 
drug absorption and allow for targeting to specific brain regions [120,121]. 
Differential Scanning Calorimetry (DSC) and Thermogravimetric Analysis (TG) 
with a support by Fourier Transform Infrared spectroscopy (FT-IR) were used for 
solid-state characterization of nanoparticles. Nanoparticles were evaluated for yield, 
drug content, morphology, size distribution and surface charge, as well as for 
mucoadhesion properties, in-vitro drug release and ex-vivo permeation ability. 
 
 
 
3.2. Materials and Methods 
 
 
3.2.1. Materials 
 
Bovine serum albumin, tacrine hydrochloride, mucin (type II: crude from porcine 
stomach) were purchased from Fluka (Milan, Italy). -cyclodextrin and 
hydroxypropyl -cyclodextrin with molar substitution degree MS 0.65 were a gift 
from Wacker Chemie GmbH (Monach, Germany), sulphobutylether -cyclodextrin 
with substitution degree DS 6.4 were a gift from CyDex Inc. (KS, USA). All the 
solvents and salts employed were purchased from Carlo Erba (Milan, Italy). 
Dimensional analysis, mucoadhesion and permeation studies were carried out in pH 
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6.0 aqueous buffer with the following composition (g/L): 7.97 KH2PO4, 3.30 
Na2HPO4∙12H2O. 
 
 
 
3.2.2. Preparation of bovine serum albumin nanoparticles 
 
Bovine serum albumin nanoparticles (nP) were prepared modifying a previously 
proposed method [119]. Briefly, 0.50 g of bovine serum albumin (BSA) were 
dissolved in 100 ml of pH 9.0 aqueous solution (10 mM NaCl) stirred magnetically 
in the presence of glass beads. Ethanol was added dropwise to this solution at a rate 
of 1.0 ml/min so as to produce a ratio 1:1 (v/v) ethanol/BSA solution and, after 
desolvation, the pH of the medium was subsequently adjusted to 9.0. Magnetic 
stirring (680 rpm) was continued at 75 °C for 60 min to yield an aqueous suspension 
of thermally cross-linked  albumin  nanoparticles. After  evaporation  of the  residual  
 
 
 
ethanol with a rotavapor, the pH was lowered to 7.0 and the final volume of 
suspension was exactly adjusted to 100 ml in order to obtain an exact amount of 
nanoparticles per volume (Fig. 3.2). Then suspensions were lyophilized (Alpha 1-2, 
Christ, Naples, Italy) and stored in a desiccator until use or employed for the loading 
process. For the preparation of nanoparticles carrying cyclodextrins (nPCD), 100 mg 
Fig.  3.2 Scheme of preparation of the Nanoparticles 
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of -cyclodextrin (CD), hydroxypropyl -cyclodextrin (HPCD) or 
sulphobutylether -cyclodextrin (SBECD) were dissolved in the aqueous albumin 
solution. The nanoparticles were formed and recovered as previously described. 
 
 
 
3.2.3. Nanoparticle loading and determination of loading efficiency 
 
THA loading into nanoparticles was achieved by soaking. For drug loading, 
nanoparticles (100 mg) were added to 20 ml of THA (2 mg/ml) in pH 7.0 aqueous 
solution (10 mM NaCl). The experiments were performed at room temperature under 
magnetic stirring. After the equilibrium was attained (24 h) the solvent was removed 
by ultracentrifugation (12000 rpm, 30 min, 4 °C) and nanoparticles were washed 
with the same aqueous solution, immediately ultracentrifugated again and finally 
freeze-dried. After the loading with THA the nanoparticles (THAnP, THAnPCD, 
THAnPHPCD, and THAnPSBECD) were stored in a desiccator until use. 
For the determination of loading efficiency an amount of 100 mg of the freeze-dried 
nanoparticles was weighed and transferred into a 10 ml volumetric flask and brought 
to volume with HCl 0.1M. The suspension obtained was sonicated for 10 min, left at 
room temperature for 20 min and then centrifuged at 3400 × g for 20 min. The 
supernatant was finally diluted in the mobile phase employed for HPLC analysis. 
The chromatographic system was composed of a Shimadzu (Milan, Italy) LC-
10ATVP chromatographic pump and a Shimadzu SPD-10AVP UV-Vis detector set 
at 240 nm. Separation was obtained on a Phenomenex (Torrance, CA, USA) Sinergy 
Fusion-RP 80A (150 x 4.6 mm I.D., 5 µm) coupled to a Phenomenex (Torrance, CA, 
USA) SecurityGuard C18 guard cartridge (4 x 3.0 mm I.D., 5 µm). The mobile phase 
was composed of a mixture of acetonitrile – pH 3.0 solution of triethylamine (0.5%) 
20:80 (v/v). The flow rate was 0.4 ml/min and manual injections were made using a 
Rheodyne 7125 injector with a 20 μl sample loop. Data processing was handled by 
means of a CromatoPlus computerised integration system (Shimadzu Italia, Milan, 
Italy). A calibration curve was set up in the 0.05–5.00 g ml−1 range; good linearity 
was found (r
2 
= 0.9997). 
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3.2.4. Particle size, zeta-potential measurements and morphology 
 
Particle size and size distributions were measured by PCS using an instrument 
(Brookhaven 90-PLUS) with an He–Ne laser beam at a wavelength of 532 nm 
(scattering angle of 90°) [122,123]. For measurement, nanoparticles were dispersed 
in pH 6.0 phosphate buffer at a 1:400 (w/v) ratio. Measurements were carried out at 
25 °C without filtering. 
Zeta-potential measurements were carried out at 25 °C on a Malvern Zetasizer 3000 
HS instrument, after the same dilution. Both average particle size and zeta-potential 
measurements were run in triplicate. 
The morphology of the particles was observed using scanning electron microscopy 
(SEM) (LEO 420 Electron Microscopy Ltd, Cambridge, England). Lyophilised 
particles were deposited on aluminium stubs using double-faced adhesive and coated 
with gold-palladium under an argon atmosphere using a gold sputter module in a 
high-vacuum evaporator, before observation. Alternatively, nanosphere suspensions 
were reconstituted in deionised water and drops were placed on aluminium stubs, 
allowed to dry and finally coated with gold-palladium as described above. 
 
 
 
 
3.2.5. Thermogravimetric analysis (TG), Differential scanning calorimetry (DSC) 
and Fourier Transform Infrared Spectroscopy (FT-IR) 
 
Mass losses were recorded with a Mettler TA 4000 (Mettler Toledo, Novate 
Milanese, MI, Italy) apparatus equipped with a TG 50 cell on 8–10 mg samples in 
open alumina crucibles (β = 10 K min−1, static air atmosphere, 30–400 °C 
temperature range). Measurements were carried out at least in triplicate (relative 
standard deviation ±5%). 
Temperature and enthalpy values were measured with a Mettler STAR
e
 system 
(Mettler Toledo, Novate Milanese, MI, Italy) equipped with a DSC821
e
 Module and 
an Intracooler device for subambient temperature analysis (Julabo FT 900) on 3–5 
mg (Mettler M3 Microbalance) samples in sealed aluminium pans with pierced lid (β 
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=10 K min
−1
, nitrogen air atmosphere (flux 50 ml min
-1
), -10 to 350 °C temperature 
range). The instrument was preventively calibrated with Indium as standard 
reference. Measurements were carried out at least in triplicate (relative standard 
deviation ±5%). 
Mid-IR (650–4000 cm−1) spectra were recorded on powder samples using a 
Spectrum One Perkin-Elmer FTIR spectrophotometer (resolution 4 cm
−1
) (Perkin 
Elmer, Wellesley, MA, US) equipped with a MIRacle
TM
 ATR device (Pike 
Technologies, Madison, WI, US). 
 
 
 
3.2.6. Mucoadhesion properties 
 
The mucoadhesion behaviour was performed as described elsewhere [124]. Briefly, 1 
ml of a mucin suspension (0.05% w/v) was mixed with 1ml of albumin nanospheres 
(0.1% w/v) for 1h and for 24 h at pH 6.0 at 37 ◦C under continuous stirring. Mucin 
nanoparticles interactions were evaluated by DLS (Dynamic Light Scattering). In 
addition the mucoadhesion ability was measured in terms of the force needed to pull 
out freshly excised sheep nasal mucosa (surface area 1 mm
2
) from a tablet (100 mg) 
with an adapted tensiometer (Krüss 132869; Hamburg, Germany) [125]. For this 
study tablets (weight of 100 mg) were prepared by direct compression of freeze-dried 
nanoparticles (compaction force: 18 kN) with a single punch press (type Korsch, 
Korsch Maschinenfabrik No. 1.0038.86, Berlin, Germany). Sheep nasal mucosa was 
obtained from local slaughterhouses. The turbinates were fully exposed by a 
longitudinal incision through the nose and the mucosa was carefully removed from 
the underlying bone by cutting with haemostatic forceps. To maintain the freshness 
of the specimen as far as possible, mucoadhesion studies were started immediately 
after the mucosa samples were excised. The nasal mucosa was fixed to a support 
with cyanoacrylate adhesive and then suspended from the tensiometer spring. The 
mucosa was lowered until it just contacted the surface of the tablet, previously 
immersed in aqueous buffer at pH 6.0 for 15 min. A 90 dyne force, measured by the 
torsion balance of the instrument as a negative force, was applied to the tablet for 30 
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s. Then the nasal mucosa was raised until it was separated from the tablet. This point 
represents the adhesive bond strength between these elements and is expressed as a 
positive force in dyne.  
 
 
 
3.2.7. In-vitro release studies 
 
In-vitro release studies were carried out as follows: loaded nanoparticles and 1 ml 
phosphate buffer solution pH 6.0 were put into a dialysis tube (MWCO: 14000) and 
then the dialysis tube was introduced into vial with 10 ml of the same buffer (sink 
condition) and the media was stirred at 100 rpm at 37 °C. At specific time intervals, 
medium was taken and replaced with fresh buffer. The concentration of the released 
THA was determined by HPLC as previously described. 
 
 
 
3.2.8. Ex-vivo permeation studies across sheep nasal mucosa 
 
The permeation study was conducted using sheep nasal mucosa in a Franz-type 
permeation cell with a diffusional area of 1.5 cm
2
. At time zero, an exact amount of 
loaded nanoparticles or an exact amount of THA was placed on the mucosa in the 
donor compartment. The receiver phase (6.0 ml of a phosphate buffer solution, pH 
6.0, maintained at 37 °C by means of a surrounding jacket) was stirred constantly 
and at predetermined time intervals samples of 100 μl were taken and replaced by 
fresh medium. The amount of THA in the receiving phase was analysed by HPLC as 
previously described. The studies were carried on for 420 min.  
 
 
3.2.9. Statistical analysis 
ANOVA was used to determine statistical significance. Differences were considered 
to be significant for values of P < 0.05. 
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3.3. Results 
 
 
3.3.1. Particle characteristics 
 
Table 3.1 shows that the % yield (calculated by dividing the dried mass of the 
particles by the dried weight of used materials and converting the weight ratio into 
percent) was higher for unloaded nanoparticles than for loaded nanoparticles, 
according to the mass loose due to ultracentrifugation and washing steps following 
THA loading into nanoparticles. 
Table 3.1 also shows that all the nanoparticles presented quite polydisperse 
populations with a mean diameter lower than 300 nm and negative zeta potential, 
even after drug loading. The presence of the native and derivatives CD and the 
loading of THA provided a significant decrease and increased in particle size, 
respectively. On the contrary, zeta potential was not significantly influenced. 
Fig. 3.3 shows SEM images of freeze-dried THAnPCD. Moreover, SEM image of 
the same reconstituted sample in deionised water (Fig. 3.4), with a higher 
magnification, shows individualized spherical shaped particles allowing observing 
that the mean particles diameter is similar to that reported for PCS data. 
 
 
 Unloaded  Loaded 
 nP nPCD nPHPCD nPSBECD  THAnP THAnPCD THAnPHPCD THAnPSBECD 
%Y 98±5 99±3 97±3 97±5  88±5 85±6 91±6 88±9 
 (nm) 221.7±11.0 159.0±9.1 145.3±9.3 132.5±12.4  266.2±12.2 189.3±10.0 199.4±13.1 177.4±18.0 
PI 0.288 0.129 0.184 0.225  0.325 0.228 0.327 0.257 
Z (mV) -11.5±0.7 -11.6±0.8 -11.3±0.7 -12.0±0.5  -10.9±0.7 -10.2±0.6 -10.5±0.8 -10.0±0.9 
% L / / / /  14.7±0.3 12.5±0.9 14.3±0.4 22.0±.05 
 
Table 3.1. % Yield (%Y), mean diameter (), polydispersity index (PI), zeta potential (Z)         
and drug loading (%L) of albumin nanoparticles. 
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3.3.2 Nanosphere loading and determination of loading efficiency 
 
Table 3.1 shows the results of drug loading process. Drug loading recovered for all 
the samples revealed the affinity of albumin nanoparticles towards THA. The 
presence of CD and HPCD in the nanoparticle network did not affect drug loading 
with respect to nanoparticles based on BSA alone. On the contrary, the presence of 
SBECD increased the drug loading. 
 
 
 
3.3.3. Thermogravimetric analysis (TG), Differential scanning calorimetry (DSC) 
and Fourier transform infrared (FT-IR) spectroscopy 
 
Fig. 3.5 shows thermogravimetric curves of native albumin (BSA) and nanoparticles 
prepared with albumin alone (nP). BSA and nP decomposed around 287 and 275 °C, 
respectively. 
In Fig. 3.6 are reported DSC curves of BSA and nP. The characteristic endothermic 
peak of the protein at 230 °C appeared in both DSC profiles, but the calculated 
enthalpy was different for the two samples. A decrease in enthalpy value of the 
Fig. 3.3  SEM image of freeze-dried 
sample of THAnPCD. 
Fig. 3.4 SEM image of freeze-dried 
nanoparticles (THAnPCD) after suspension 
reconstitution. 
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endothermic effect in nP, compared to BSA, is evident indicating a partially loss of 
protein structure organization during thermal cross-linking. 
Accordingly to a previous work [119] FT-IR spectra of BSA and nP were recorded in 
order  to confirm  albumin  denaturation after ethanol-induced coacervation followed  
 
 
 
 
Fig.  3.6 DSC curves of native albumin (BSA) and nanoparticles prepared                                 
with albumin alone (nP). 
Fig.  3.5 TGA curves of native albumin (BSA) and nanoparticles  prepared with 
albumin alone (nP). 
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Fig.  3.7  FT-IR spectra of THA, THAnP, THAnPCD, THAnPHP-CD and THAnPSBE-CD. 
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by  thermal  cross-linking. As in acetone-induced  coacervation  followed by  thermal  
cross-linking, BSA and nP presented the same protein characteristic peaks relative to 
C-O stretching vibration (amide I band) and to a mix vibration of N-H bending and 
C-N stretching (amide II band), but the band intensities and frequencies appeared 
modified (data not reported). 
In Fig. 3.7 are reported the FT-IR spectra of THA, THAnP, THAnPCD, THAnPHPCD 
and THAnPSBECD. The THA characteristic band at 765 cm
-1
, assignable for aromatic 
C-H, is evident in the THAnP system and disappears in those carrying native and 
derivatives CD, probably as a consequence of an interaction between the drug and 
the albumin/cyclodextrin network. 
 
 
 
3.3.4. Mucoadhesion properties 
 
Mucin/nanosphere aggregates presented higher dimensions than the standard samples 
(Fig. 3.8). In particular, nanoparticles carrying HPCD increased their mean size of 
ten times after 24 h showing the best mucodhesion properties. These results were 
confirmed by experimental detachment forces (n = 5, the SD did not exceed the 5%): 
nP, 20 dyne; nPCD, 29 dyne; nPHPCD, 65 dyne; nPSBECD, 30 dyne. 
 
 
 
3.3.5. In-vitro release studies 
 
Table 3.1 shows the fractional amount of THA released from nanoparticles 30, 180 
and 400 min after the beginning of the experiment. Data indicated that THA release 
did not occur immediately but a sustained release was obtained for all nanoparticles. 
Moreover, nPSBECD provided lower release than the other particulate systems 
accordingly to the good THA affinity for these systems as observed during loading 
experiments. 
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Fig.  3.8  Mean diameter of mucin (mean ± SD, n = 5), nanoparticles and 
mucin/nanoparticle aggregates measured by Dynamic Light Scattering. 
Fig.  3.9  Permeation profiles profiles (mean ± SD, n = 3) of tacrine hydrochloride 
from loaded nanoparticles. 
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3.3.6. Ex-vivo permeation studies across sheep nasal mucosa 
Fig. 3.9 shows the permeation profiles of THA after nanoparticles placement on 
sheep nasal mucosa. THA standard solution presented the best permeation profile, 
allowing 100% drug permeation in 100 min. Nanoparticles showed sustained 
permeation profiles and in particular nanoparticles containing the different 
cyclodextrins revealed enhanced THA permeation with respect to nanoparticles 
based on albumin alone. 
 
 
 
3.4. Discussion 
 
Nanoparticles were obtained modifying a method previously employed [119]. 
Albumin coacervation with ethanol followed by thermal cross-linking produced 
albumin nanoparticles with size and polydispersity higher than those obtained by 
coacervation with acetone. The choice for ethanol-induced coacervation stands in the 
possibility to reduce particle potential toxicity due to the permanence of solvents. In 
fact, acetone can damage mucosal epithelia and it has been shown to have 
anticonvulsant effects in animal models of epilepsy, when administered in very small 
(millimolar) concentrations [126]. For these reasons the presence of acetone in nasal 
dosage forms, albeit in small quantities, should be avoided. Moreover, in a recent 
study Adriaens and co-authors [127] reported that acetone can produce membrane 
damage at concentrations of 5% (w/v), while ethanol was shown to induce severe 
irritation (increased mucus production, protein and LDH release) only at 
concentration of 10% (w/v), whereas concentrations of 5% (w/v) and lower has no 
effect. Albumin denaturation was confirmed by thermal data supported by FT-IR 
spectra. In particular, the shift to lower temperature of the thermal degradation of nP 
indicated a loss of protein organization due to the formation of new bonds between 
albumin molecules. Moreover, the lowering in the enthalpy values calculated from 
DSC curves confirmed that albumin lost its native structure during the denaturation 
process. Finally, FT-IR spectra behaviour could be associated with the destruction of 
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hydrogen bounds through heat denaturation and reflected a decrease in alfa-helix 
content of the denaturated protein. 
As can be observed in Table 3.1, the presence of the CD, native and derivatives, in 
the particle structure influenced their size. As reported by Csaba and co-authors 
[128] particle size can be correlated to the viscosity of the solution before polymer 
coacervation. Viscosities of albumin solutions in the presence or in the absence of 
the different CDs was measured by means of an Ubbelohde capillary viscometer 
equipped with an electronic time-measuring unit ViscoClock (Schott, Mainz, 
Germany) and were found not significantly different (0.97±0.08 cP for nP, 0.98±0.04 
cP for nPCD, 0.98±0.04 cP for THAnPHPCD and 0.97±0.07 cP for THAnPSBECD). 
These data confirmed that albumin molecules were greatly solubilised in the solution 
due to the high repulsive forces existing at pH 9.0 and that cyclodextrins/albumin 
interactions in the solution did not cause variation of viscosity. However, Ko and 
Gunasekaran [129] reported that, for preparing nanoparticles of small size, high 
protein unfolding and low hydrophobic interactions of protein molecules are 
extremely important. We hypothesize that the presence of the different CDs in the 
solution could mask the hydrophobic regions of albumin molecules thus suppressing 
their interactions and improving protein unfolding. For instance, during albumin 
coacervation in the presence of the different CDs, the great protein unfolding 
favoured the formation of nanoparticles with smaller size.  
The increased particle size after drug loading suggests that THA molecules could 
interact with nP due to physical absorption improved by ionic interactions. In fact, as 
confirmed by zeta potential measurements, at pH > 6.0 albumin nanoparticles 
(albumin P.I., 4.6) were negatively charged due to the presence of much more 
carboxylic groups than amino groups [119], while THA (pKa, 9.85) showed a 
positive charge. 
Shape of the samples was analysed by electron microscopy. In particular, Fig. 3.4 
shows individualized particles with mean diameter consistent with that measured by 
PCS, indicating that nanoparticles were discrete entities and that lyophilisation 
process produced a reversible aggregation of nanoparticles. 
Loading data suggest that THA had great affinity for all albumin-based nanoparticles 
and the presence of SBECD allowed entrapping the highest amount of drug. In fact, 
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SBECD, due to its negative charges, could increase the charge density on the 
nanoparticle surface thus improving the absorption of the positive charged THA. 
This behaviour was also confirmed by the lower in-vitro release of THA from 
nPSBECD compared to the other nanoparticles. 
Only nanoparticles without CDs showed the characteristic band of THA at 765 cm-1 
in FT-IR spectra. Otherwise the absence of this band in drug/nanoparticle carrying 
CDs suggested the presence of interactions between the drug and the 
albumin/cyclodextrins network. 
As described in a previous work [119], nP showed mucoadhesion properties in in-
vitro and ex-vivo studies. Also albumin nanoparticles carrying the different CDs 
maintained the same characteristics and in particular nPHPCD showed the highest 
mucoadhesive ability. Mucoadhesion is affected by the synergistic action of the 
properties of the polymeric delivery system and the biological environment. The 
interactions between mucus and hydrophilic polymers are a result of physical 
entanglement and secondary bonding related to the chemical groups of the polymeric 
chain. Moreover, polymers hydration ability, increasing the mobility of molecules, 
facilitates interpenetration and interaction with the mucus layer [130-132].We 
hypothesize that nanoparticles have different ability to hydrate accordingly to the 
different solubility of the loaded CDs. In particular, CD has the lowest solubility 
(18 mg/ml), while HPCD and SBECD have higher solubility (>600 mg/ml and 
>500 mg/ml, respectively) [133]. The lower mucoadhesiveness of nPSBECD with 
respect to nPHPCD could be attributed to the presence of the higher electrostatic 
repulsive forces arising from the ionized functional groups of SBECD loaded in the 
nanoparticles and sialic acid (pKa, 2.6) of the mucus. 
Generally, non mucoadhesive formulations can be rapidly cleared from the nasal 
cavity by mucociliary mechanism, thus providing short residence times and low drug 
bioavailability. All nanoparticles produced lower drug permeation than THA 
standard solution (Fig. 3.9), but good adhesion to nasal mucosa. This behaviour 
suggests that they could be suitable delivery systems for improving nasal drug 
bioavailability. Moreover, the presence of the different CDs, particularly HPCD, 
favoured drug permeation with respect to nanoparticles based on albumin alone. In 
fact, a decrease in lag time and an increase in the flux could be observed and 
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correlated to CDs ability to interact with the lipophilic components of biological 
membranes changing their permeability. 
 
 
3.5. Conclusions 
 
The results in this study indicate that albumin nanoparticles carrying native and 
hydrophilic derivatives CD can be employed for the formulation of mucoadhesive 
nasal formulations with interesting drug permeation properties. The selection of 
suitable CD during particle preparation allows the modulation of their mucoadhesion 
ability and THA permeation at the administration site. This work will be furthered by 
performing intranasal absorption studies in animal models. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Multifunctional liposomes for delivery of the anti-Alzheimer drug tacrine hydrochloride by the 
nasal route. Part 1
 
 
   Giuseppe Corace                                   Page 73 of 130                                  University of Bologna      
 
 
 
 
4. MULTIFUNCTIONAL LIPOSOMES FOR DELIVERY OF THE ANTI-
ALZHEIMER DRUG TACRINE HYDROCHLORIDE BY THE NASAL 
ROUTE. PART 1: FORMULATION, CHARACTERIZATION, IN-
VITRO/EX-VIVO PERMEABILITY AND NEURONAL UPTAKE 
EVALUATION 
 
  
 
 
 
Fig.  4.1  Graphical Abstract. Improvements achieved by the addition of α-Tocopherol and 
Poliunsaturated Fatty Acid (Ω3) in the liposome formulations 
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4.1. Introduction 
 
Alzheimer's disease (AD) is a fatal neurodegenerative condition characterized 
clinically by progressive memory loss and irreversible cognitive deterioration. It has 
been shown that there is a progressive degeneration of the brain’s acetylcholine 
neurons which leads to the appearance of cognitive symptoms of the disease. At 
present, there are no therapeutic interventions able to stop the progression or to treat 
brain degeneration. Treatments are therefore aimed at slowing down the worsening 
course, maintaining, at least temporarily, the cognitive and behavioural symptoms, 
thus ensuring patients to have good or decent quality of life. One strategy to combat 
this disease is to increase cholinergic transmission; therefore acetylcholinesterase 
inhibitors have been developed including tacrine, rivastigmine and donepezil [134-
137]. Although the aetiology is not still understood, it appears that oxidative stress 
(OS) plays a central role in the pathogenesis and progression of the AD [138] and 
then it would be desirable to integrate traditional therapeutic strategy, based on the 
recovery of the acetylcholine deficit, with an antioxidant treatment. In fact, 
epidemiological investigations have shown an improvement in cognitive activity and 
a slowing of disease progression following the administration of antioxidants. In 
addition, α-tocopherol (Toc) administration has been shown to reduce hepatotoxic 
effects of the anti-Alzheimer drug tacrine and can be considered a suitable adjunct to 
tacrine therapy [139]. Moreover, it has recently been shown that when the brain is 
rich in docosahexaenoic acid (DHA), an omega-3 fatty acid which can also be 
biosynthesized starting from α-linolenic acid, production of amyloid plaques is 
lower, with a decrease of the characteristic symptoms of the disease. Tacrine 
(1,2,3,4-tetrahydro-9-aminoacridine) (THA), one of the drugs approved by the FDA 
for the treatment of Alzheimer’s disease [140,141], is present in the market only as 
oral formulation. However, peroral THA administration is associated with low 
bioavailability, due to the extensive hepatic first-pass effect and the rapid clearance 
from the systemic circulation, and with a reversible dose-dependent hepatotoxicity 
and peripherical cholinergic side effect [142,143]. Hence, alternative routes of 
administration for the centrally active acetylcholinesterase inhibitor THA may offer 
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distinct advantages. Drug delivery from the nose to the CNS can be achieved via 
olfactory neuroepithelium and can involve paracellular (inter cellular spaces and 
tight junction), transcellular (passive diffusion, active transport and transcytosis) 
and/or neuronal transport [144, 145]. Moreover, the transport via trigeminal nerve 
system from the nasal cavity to CNS has also been described [146]. THA delivery 
into CNS through intranasal route has been reported both in humans and in animal 
models of Alzheimer’s disease and its administration by intranasal route not only has 
been found useful for circumventing the blood-brain barrier, but also for avoiding the 
hepatic first-pass effect, thus allowing lower dosage and side effects [147]. The 
current oral dosing regimen for THA is 40 mg/day (10 mg 4 times daily). The 
possibility to administer a lower THA dosage depends on the formulation ability to 
interact with the mucus layer and mucosal epithelium, as well as promote drug 
permeation during their residence in the nasal cavity, thus to their ability to allow 
complete absorption of the encapsulated drug [148]. In the last few years, different 
kinds of liposomes have been evaluated as potential intranasal drug delivery systems; 
moreover, Mahmoud Reza Jaafari et al. have demonstrated that nasal clearance half-
lives of liposomes were at least four-fold than normal clearance half-life of human 
nose (about 20 min), thus suggesting that these particulate systems are highly 
mucoadhesive [149]. The permeability-enhancing effect of liposomes has also been 
demonstrated and may be increased by adding to the formulation substances that can 
promote lipid vesicles fusion with cellular membrane. As reported by Nakagawa H. 
et al. [150] the presence of isoprenoids, like Toc, in liposome bilayer improves the 
ability of phospholipid vesicles to fuse with cellular membrane. In addition, Toc in 
liposomes acts as a membrane stabilizing agent, reducing liposome drug leaking and 
avoiding lipid oxidation [151].  
In this work, the capacity of Toc and polyunsaturated fatty acids (Ω3) in liposome 
formulations to influence drug permeability and neuronal uptake was evaluated. The 
antioxidant and neuroprotective properties of our multifunctional liposomes have 
been going evaluating and will be reported in details in the chapter 5.   
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4.2. Materials and Methods 
 
 
 
4.2.1. Materials 
 
Tacrine hydrochloride (THA), α-tocopherol, L-α-phosphatidylcholine from egg yolk 
and cholesterol were purchased from Fluka (Milan, Italy). Eicosapentaenoic acid and 
docosahexaenoic acid were obtained from Doosan Serdary Research Laboratories 
(Englewood Cliffs, NJ). Egg phosphatidylcholine, Lipoid E-80, was kindly provided 
by Lipoid GmbH (Ludwigshafen, Germany). Triton X-100, calcein and Dulbecco’s 
modified Eagle’s medium (DMEM), fetal calf serum (FCS), 
penicillin/streptomycin,were purchased from Sigma-Aldrich (Milan, Italy). Clear 
culture Transwell inserts (diameter 6.5 mm) and plates were obtained from Corning 
GmbH, Life Sciences (Wiesbaden, Germany). Clear Millicell cell culture plates (24 
well) were purchased from Millipore A/S (Copenhagen, Denmark). All the solvents 
and salts were purchased from Carlo Erba (Milan, Italy). Phosphate buffer pH 6.0 
and pH 7.4 had the following composition (g/L): 7.97 KH2PO4, 3.30 
Na2HPO4*12H2O and 0.60 KH2PO4, 6.40 Na2HPO4*12H2O, 7.42 NaCl respectively. 
 
 
 
4.2.2. Determination of THA octanol/phosphate buffer solution PBS (pH 7.4 and 
6.0) distribution coefficient (LogD) 
 
LogD [152] values at pH 6.0 and 7.4 were determined using a new method, based on 
Nuclear Magnetic Resonance (NMR) spectroscopy. In particular, the method is 
based on localized 
1
H NMR spectroscopy, measuring simultaneously, in situ, the 
concentration of THA in both phosphate buffer (PBS) and octanol phases, without 
disturbing the interface [153]. Briefly, 300 μL of THA solution (5mg/mL in PBS pH 
6.0 or 7.4) were placed on the bottom of a standard 5 mm od NMR tube. 300 μL of 
1-Octanol were placed above the THA solution. After 72 hours (time required for 
equilibration [153]) spectra of the two phases were recorded simultaneously and 
4. Multifunctional liposomes for delivery of the anti-Alzheimer drug tacrine hydrochloride by the 
nasal route. Part 1
 
 
   Giuseppe Corace                                   Page 77 of 130                                  University of Bologna      
analyzed. The experiments were carried out on a Varian INNOVA 500 spectrometer 
operating at a proton frequency of 499.845 MHz and equipped with performa II 
gradient amplifiers. The water signal was suppressed using presaturation. The 
experiments were performed without deuterium lock, as no 
2
H was present in the 
solvents. A standard sample containing PBS and 10% D2O was used for shimming 
and referencing purpose. The experiments were performed at 25 
o
C. 
 
 
 
 
4.2.3. Preparation of liposomes 
 
Liposomes were prepared by a modified Reverse-Phase Evaporation Vesicles 
technique [154-156]. Different unloaded (α, β, γ and δ) and THA loaded (A, B, C 
and D) liposome formulations were prepared according to the following lipid 
compositions (molar percentage): L-α-phosphatidylcholine from egg yolk (EPC) 
60% and cholesterol (CHO) 40% for Lipo A and Lipo α; EPC 60%, Toc 13% and 
CHO 27% for Lipo B and Lipo β; EPC 60%, Ω3 13% and CHO 27% for Lipo C and 
Lipo γ; EPC 60%, Toc 13%, Ω3 13% and CHO 14% for Lipo D and Lipo δ. Briefly, 
lipid mixture (800 μmol in total) was dissolved in 75 mL of diethyl ether; 25 mL of 
physiological buffered solution (0.9% NaCl, pH 6.0 and 295 mOsm/L) of THA (0.45 
mg/mL) were then added to the organic solution and the resulting biphasic system 
was emulsified by sonication at 4 °C in a bath-type ultrasonic cleaner, until the 
water/oil emulsion became clear. Finally, the organic solvent was removed under 
reduced pressure (Buchi Rotavapor R-200, Flawil,CH; 400 bar, 15°C, 210 rpm). 
When the majority of the solvent was removed, a significant increase in viscosity 
(gel-like) appeared and the emulsion subsequently converted into an aqueous 
liposomal dispersion. The time needed to achieve this conversion was dependent on 
the lipid composition; in fact, a more rapid inversion was obtained for formulations 
Lipo A and Lipo α (20 min) with respect to the other formulations (60 min); all 
liposomal dispersions were diluted 1:1 with physiological buffer solution. In order to 
obtain small and homogeneous liposomes, all the suspensions were sequentially 
extruded through 800 nm, 400 nm, 200 nm and 100 nm pore size polycarbonate filter  
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Table  4.1  Final lipid concentrations in liposome formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Nucleopore, Pleasanton, CA), by using an extruder (DE; Liposo-Fast
TM
-Basic, 
Avestin Inc., Ottawa, Canada). For all the extruded liposomes the encapsulation 
efficiency was evaluated (see section 2.4). The free THA was removed from loaded 
liposomes by ultracentrifugation (4 hours, 42029 g and 4°C). The liposomal fractions 
were washed twice and then diluted to 50 mL with fresh physiological buffer 
solution. Final lipid concentration is reported in Table 4.1. These liposomes were 
used for the subsequent experiments. 
 
 
 
4.2.4. Liposome size distribution and zeta-potential measurements  
 
Liposome size distribution was measured by PCS (Photon-Correlation Spectroscopy) 
using an instrument (Brookhaven 90-PLUS) with He–Ne laser beam at a wavelength 
of 532 nm (scattering angle of 90°). For size measurements, liposome suspensions 
were diluted (1:400; v/v) in ultra-filtered physiological buffer solution. The 
dispersions were stirred at 25°C for 30 min and then analyzed without filtering. Zeta-
potential measurements were carried out at 25°C on a Malvern Zetasizer 3000 HS 
LIPOSOMES EPC (mM) Ω-3a  (mM) Toc (mM) CHO  (mM) 
Lipo A 9.60   6.40 
Lipo α 9.60   6.40 
Lipo B 9.60  2.08 4.32 
Lipo β 9.60  2.08 4.32 
Lipo C 9.60 2.08  4.32 
Lipo γ 9.60 2.08  4.32 
Lipo D 9.60 2.08 2.08 2.24 
Lipo δ 9.60 2.08 2.08 2.24 
aΩ3 = 60% eicosapentaenoic acid (EPA), 40% docosahexaenoic acid (DHA) 
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instrument, after the same dilution. Both liposome average size and zeta-potential 
measurements were run six times. 
 
 
 
4.2.5. Determination of encapsulation efficiency  
 
Encapsulation efficiency was determined after liposome extrusion. Separation 
technique of liposomal and non-liposomal THA is based upon the property of 
liposomes to cross reversed-phase C18 silica gel cartridges without being retained,  
 
 
Fig. 4.2  Solid Phase Extraction (SPE) diagram used to separate liposomal and non- 
liposomal encapsulated THA 
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while THA retained on the stationary phase can be eluted with methanol as 
illustrated in Fig. 4.2 [157]. Briefly, liposome suspension (50 µL) was passed through 
a Sep-Pak C18 cartridge (Waters Corporation, Milford, Massachusetts, USA) 
conditioned with 3 mL methanol and 6 mL physiological buffer solution at pH 9.5. 
The eluate containing liposomal THA was collected in a 10-mL tube containing 100 
µL of 20% (v/v) Triton X-100 in water; then 4 mL of physiological buffer solution at 
pH 9.5 was finally passed through the cartridge and all eluates were collected 
together in the Triton X-100-containing tube. Finally, the non-liposomal THA was 
eluted with two portions of 1.5 mL of methanol and recovered by evaporation in a 
rotavapor. The liposome-associated THA-fraction recovered in Triton X-100 was 
vortex-mixed vigorously, sonicated for 30 minutes at 60°C in a bath-type cleaner and 
slowly passed through a new conditioned Sep-Pak C18 cartridge. The aqueous eluate 
was discarded, while THA was eluted with two portions of 1.5 mL of methanol. The 
methanol eluate was collected in a tube and recovered by evaporation in a rotavapor. 
The two dried residues were reconstituted with 10 mL of mobile phase and liposomal 
and non-liposomal THA was determined by HPLC analysis using Shimadzu (Milan, 
Italy) LC-10ATVP chromatographic pump and a Shimadzu SPD-10AVP UV-Vis 
detector set at 240 nm. Separation was obtained on a Phenomenex (Torrance, CA, 
USA) Sinergy Fusion-RP 80A (150 x 4.6 mm I.D., 5 µm) coupled to a Phenomenex 
(Torrance, CA, USA) SecurityGuard C18 guard cartridge (4 x 3.0 mm I.D., 5 µm). 
The mobile phase was composed of a mixture of acetonitrile - methanol - pH 6.5 
solution of triethylamine (1.4%) 20:10:70 (v/v). The flow rate was 0.4 mL/min and 
manual injections were made using a Rheodyne 7125 injector with a 20 μL sample 
loop. A calibration curve was set up in the 0.05–5.00 g ml−1 range; good linearity 
was found (r
2 
= 0.9998).  
Encapsulation Efficiency % was calculated according to the following equation: 
 
EE% = [(THAin / THAin  + THAout)] x 100                     (1) 
 
where THAin  and THAout are the amount of liposomal and non-liposomal THA, 
respectively.  
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4.2.6. Ex-vivo Mucoadhesion Studies 
 
The mucoadhesion behaviour was tested determining the residence time on sheep 
nasal mucosa as described elsewhere [158]. Briefly, sheep nasal mucosa was 
obtained from local slaughterhouses and the time from slaughter to removal of the 
nose was 5 min maximum. The excised tissue was stored directly on ice during 
transportation to the laboratory, where turbinates were fully exposed by a 
longitudinal incision through the nose and the mucosa carefully removed from the 
underlying bone [159]. To maintain the freshness of the specimen as far as possible, 
mucoadhesion studies were started immediately after the mucosa samples were 
excised and carried out within 3 hours of procurement of the mucosa; in addition, to 
ensure the tissue viability, experiments were conducted in oxygen-enriched 
atmosphere, blowing on the nasal mucosa a gas mixture composed by 95% of O2 and 
5% of CO2.  An exact amount of liposome dispersions (200 µL) were placed on the 
mucosal surface (2.0 cm
2
), which was attached, with cyanoacrylate glue, over a 
polyethylene support fixed in an angle of 30° relative to the horizontal plane. 
Immediately after liposomes placement on mucosal surface, the mucosa was 
thoroughly washed with physiological buffered solution pH 6.0, at the rate of 0.5 
ml/min using a peristaltic pump. At predetermined time intervals, samples of 100 μl 
were taken and replaced by fresh medium. Then, samples were treated with Triton X-
100 and the amount of THA was analysed by HPLC, using the same conditions 
previously employed. 
Mucoadhesion (%) was calculated according to the following equation: 
 
Mucoadhesion (%) = [(M0-Mp)/M0] x 100      (2) 
 
Where M0 is the total drug and Mp is the drug recovered in the perfusate at each time.    
 
 
 
 
4. Multifunctional liposomes for delivery of the anti-Alzheimer drug tacrine hydrochloride by the 
nasal route. Part 1
 
 
   Giuseppe Corace                                   Page 82 of 130                                  University of Bologna      
4.2.7. Evaluation of THA apparent permeability (PAPP) using the Phospholipid 
Vesicle-based Permeation Assay (PVPA) 
 
PVPA is a technique based on deposited liposomes on filter supports in culture 
inserts, forming a barrier for transport studies. Phospholipid vesicle based barriers 
were prepared according to the protocol developed by Flaten GE. et al. [160,161]. 
Briefly, mixed cellulose ester filters (pore size 0.6 μm, Millipore A/S, Copenhagen, 
Denmark) were sealed by heat (150°C, 25s) on Millicell filter holders  (custom-
produced by Millipore A/S, Copenhagen, Denmark) using custom-made sealing 
machine (IBR-Ingenieurbüro, Waldkirch, Germany). Liposomes were prepared by 
film hydration/filter extrusion using egg phosphatidylcoline Lipoid E80 (Lipoid 
GmbH, Ludwigshafen, Germany).Liposome dispersion was extruded through 0.8 and 
0.4 μm polycarbonate membrane filters (Millipore) to obtain liposomes with two 
different mean sizes, which were subsequently spun down (first the liposomes with 
size of 0.4 μm and subsequently those with size of 0.8 μm) on filter inserts. Finally, 
to promote the liposome fusion and obtain tight barriers, inserts were frozen at -80°C 
and thawed at 65°C. Permeation studies were performed over 200 min. Briefly, 
phospholipid vesicle based barriers were pre-incubated with phosphate buffer pH 6.0 
for 60 min. Subsequently, inserts were moved to a new plate with the wells filled 
(acceptor chambers) with 600 µL phosphate buffer pH 6.0; at time zero 400 µL of 
THA solution (65μg/mL, 0.9% NaCl) or 400 µL of loaded liposomes (A, B, C and 
D) were added to each insert (donor chamber). At predetermined time intervals (30, 
60, 80, 100, 120, 140, 160, 180 and 200 min) inserts were moved to a new plate in 
order to assure sink condition. Samples of 300 µL were taken from each acceptor 
chamber and the amount of permeated THA was analyzed by HPLC as previously 
described. The cumulative amount of permeated THA was plotted against the time 
obtaining a curve. The slope of the linear part, representing steady state flux (J), was 
used to calculate the apparent permeability coefficient (PAPP) according to the 
following equation:  
PAPP (cm/s) = J / Cd x A        (3) 
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where A is the area of the insert used and Cd is the initial donor concentration. 
Electrical resistance (ER) across the barrier and the calcein flux were measured in 
order to test the integrity of the membrane. The ER of the lipid barriers was 
measured using a Millicell-ERS (Millipore GmbH, Schwalbach, Germany) 
immediately after completion of the permeation studies. Calcein flux was also 
evaluated as a parameter to define the integrity of the barriers; in fact, calcein at pH 
7.4 is charged, so its PAPP should be very low. Barriers were considered tight when 
the ER values at the end of permeation experiment were between 100% and 90% of 
the initial ER values and the calcein PAPP values were lower than 0.1 x 10
-6
 cm/s. The 
experiments were performed in six parallels for each liposome formulation and THA 
solution. 
 
 
4.2.8. Evaluation of THA permeability (P) using Ex-vivo Sheep Nasal mucosa 
Permeation Assay (ENSPA) 
 
Permeation studies were conducted using sheep nasal mucosa obtained as previously 
described. The excised nasal mucosa was put between the donor and receptor 
compartments of the Franz diffusion cell with a diffusional area of 1.5 cm
2
. The 
mucosal surface of the nasal mucosa faced the donor compartment and the serosal 
surface faced the receptor compartment. At time zero, 150 µL of loaded liposomes 
(A, B, C and D) or 150 µL of THA solution (65 µg/mL, 0.9% NaCl) were placed on 
the mucosa in the donor compartment. The receiver phase (6.0 mL of PBS pH 6.0, 
maintained at 37° C by means of a surrounding jacket and oxygen-enriched by 
bubbling a mixture of O2-CO2  (95-5%) for 15 minutes before being inserted in the 
receiver compartment), was stirred constantly and at predetermined time intervals 
(10 minutes) samples of 100 μl were taken and replaced by fresh medium. The 
amount of THA in the receiving phase was analysed by HPLC as previously 
described. The studies were carried on for 80 minutes. Flux data were plotted as the 
cumulative amount of drug diffused from the mucosal to the serosal side of 
epithelium versus time. The permeability coefficient (P) was calculated using the 
equation (3) previously described. 
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4.2.9. Assessment of tacrine uptake/association in SH-SY5Y cell line  
 
Human neuroblastoma SH-SY5Y cell line was routinely grown at 37°C in a 
humidified incubator with 5% CO2 in DMEM supplemented with 10% FCS, 2 mM 
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin as previously reported 
[162]. Cells with 15–20 passages were used. SH-SY5Y cells were seeded in culture 
dishes (size 100 mm) at 1.0 10
6
 cells/dish. To evaluate the cell-associated levels of 
THA, SH-SY5Y cells were treated with 35 µL of loaded liposomes (Lipo A, Lipo B, 
Lipo C and Lipo D) / mL of medium (corresponding at a final THA concentration of 
10 µM) or THA solution 10 µM for 24 h. Cells were washed four times with ice-cold 
PBS to ensure not associated THA removal and rapidly lysed on ice using aqueous 
methanol (50% v/v) containing HCl (0.1%). SH-SY5Y cells were scraped off and 
left on ice to solubilize for 45 min, then centrifuged at 2000 g for 5 min at 4 °C to 
remove unbroken cell debris and nuclei. THA contained  in the supernatants was 
determined by HPLC analysis using Beckman Coulter (Milan, Italy) 125 S pump 
Solvent Module and a Shimadzu Fluorescence Detector Model RF-551 (excitation: 
330nm and emission: 365nm). Separation was obtained on Beckman Coulter (Milan, 
Italy) Ultrasphere ODS (4.6 mm x 25 cm, 5 μm). The mobile phase used was the 
same as previously described (section 2.4). The protein concentration in the 
supernatants was determined by the Bio-Rad Bradford protein assay (Bio-Rad 
Laboratories, Hercules, CA, USA). 
 
 
 
4.2.10. Statistical analysis 
 
 Each experiment was performed at least six times, and all values are represented as 
means ± standard error of the mean (SEM). One-way analysis of variance (ANOVA) 
was used to compare differences among data sets. Generally, values P < 0.05 were 
considered to be statistically significant. 
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4.3. Results and discussion 
 
 
 
4.3.1. Evaluation of THA LogD 
 
The distribution coefficients (LogD) of THA were calculated by dividing the total 
area underneath THA aromatic hydrogen peaks in the spectrum recorded in the 
octanol phase with those recorded in the PBS phase (Fig. 4.3). As expected, LogD 
values were negative suggesting that THA can locate mainly in the aqueous phase of 
a liposome system. Moreover, the LogD value obtained with pH 7.4 was higher (-
0.617) than pH 6.0 (-0.978) accordingly to the higher ionization degree of THA in 
the acidic environment.  On this basis, the Reverse-Phase Evaporation Vesicles 
technique followed by extrusion (French press) was chosen for liposome preparation 
obtaining unilamellar vesicles characterized by an increased trapped aqueous volume 
(LUV) and thus increased encapsulation efficiency. In addition, aqueous solution 
(0.9% NaCl, pH 5.95 and 295 mOsm/L) was used for liposome preparation in order 
to favour drug-phospholipids ionic interaction and greater drug loading.  
 
Fig. 4.3  
1
H NMR spectra of the aromatic protons of THA in 1-octanol and in phosphate buffer 
solution (PBS) at pH 7.4 and 6.0. The phase change is for display purposes only. 
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4.3.2. Physical properties of liposomes 
 
Size and charge of THA loaded and unloaded liposomes were investigated by 
measuring their mean size and polydispersity index (PI) as well as zeta potential (Z) 
and compared with THA encapsulation efficiency (EE%). The results are 
summarized in Table 4.2. After mechanical extrusion, all liposomal formulations 
showed low PI values below 0.25, which indicates good size homogeneity. No 
significant difference in mean size was seen between loaded and unloaded 
liposomes, while there were minor, yet significant, differences between the different 
formulations. The mean diameters of conventional liposome formulation (Lipo A and 
Lipo α) were lower than the mean diameters of liposomes containing Toc (Lipo B 
and Lipo β) or Toc and Ω3 (Lipo D and Lipo δ). We hypothesize that the presence of 
Toc could slightly increase liposome size due to an increased flexibility of the 
vesicles which could more easily cross the polycarbonate filter without being broken 
[163]. 
Zeta potential was negative for all studied liposomal formulations. In particular, Lipo 
γ and Lipo δ which contain Ω3 presented lower Z potential values than Lipo α and 
Lipo β. This could also explain the increased encapsulation efficiency (Table 4.2) 
detected for Lipo C and Lipo D. The positively charged THA is expected to interact 
to a higher extent with a more negative liposome system.   
Encapsulation efficiency values (Table 4.2) highlight that the technique and 
operating parameters used for liposome preparation were promising; in fact, the EE% 
(about 30% for all liposome formulations) was particularly high compared to others 
liposome formulations encapsulating drug with similar Log D and prepared with 
different techniques [164]. On the basis of EE% data and liposome dilution (50 mL), 
the final THA concentration in the liposomes formulation was 285.36 μM, 304.91 
μM, 308.84 μM and 313.35 μM for Lipo A, B, C and D, respectively. 
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Table 4.2  Mean Diameter (), Polydispersity Index (PI), Zeta Potential (Z) and Encapsulation 
Efficiency (EE%). 
 
 
4.3.3. Ex-Vivo mucoadhesion study 
 
Mucoadhesion is an important property for a system which has to be administered by 
nasal route; it provides information on the permanence of a formulation on the nasal 
mucosa, contrasting the high mucociliary clearance, which has a speed of 5 mm/min 
in healthy humans (15-20 min to cross human nasal cavity) [165, 166]. Fig. 4.4 
shows THA solution and loaded liposome (A, B, C and D) residence times on 
excised sheep nasal mucosa. After 30 minutes from application, only 19.41 ± 1.45% 
of THA remained on nasal mucosa, highlighting poor mucoadhesivity of the free 
drug and the need to encapsulate THA in a system able to increase residence time 
and, therefore, favour its permeation. Moreover, all liposome formulations presented 
higher mucoadhesion ability than THA solution (p < 0.001), confirming the results 
obtained by Quinn PJ [151]. Particularly, after 30 minutes from application of Lipo 
A, Lipo B, Lipo C and Lipo D on the mucosa, the percentage of THA that remained 
adhered on nasal mucosa was 68.54 ± 2.07 %, 72.85 ± 1.95 %, 67.91 ± 3.24 % and 
71.23 ± 2.49 %, respectively. In comparison to others liposome formulations Lipo A 
showed lower mucoadhesion ability, which became significant after 90 minutes (p < 
0.05), suggesting that the presence of Toc and/or Ω3 in the phospholipid vesicles can 
improve their interaction with the cell surface.  
Unloaded Loaded 
Lipo α Lipo β Lipo γ Lipo δ Lipo A Lipo B Lipo C Lipo D 
 (nm) 175.7 ± 0.7 197.2 ± 4.7 208.8 ± 4.5 190.6 ± 3.8 181.8 ± 3.0 192.4 ± 2.9 179.3 ± 8.1 219.3 ± 4.2 
PI 0.146 0.194 0.203 0.185 0.225 0.186 0.215 0.213 
Z (mV) -12.9 ± 0.8 -13.3 ± 1.9 -16.8 ± 0.2 -17.0 ± 1.3 -14.0 ± 1.1 -14.5 ± 0.6 -16.2 ± 1.7 -16.8 ± 0.9 
EE% / / / / 29.77±1.32 31.81±1.62 32.22±1.05 32.69±1.39 
Mean  ± SEM, n = 6 
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4.3.4. THA permeability 
 
With regard to in-vitro permeation assay (PVPA), the trans-barrier electrical 
resistance (ER) was evaluated in order to assess the phospholipid vesicles barrier 
integrity in presence of the formulations. The electrical resistance after the 
permeation assay (data not shown) was in all cases found slightly lower (by about 
10%) as compared to the one before, so the barriers could be considered intact. In 
addition, the apparent permeability (PAPP) of the hydrophilic marker calcein across 
phospholipid vesicles barrier was 0.07 ± 0.01 x 10
-6
 cm/s, further confirming the 
barrier integrity. Fig. 4.5 shows the permeability values (PAPP and P) of THA in 
solution and THA encapsulated in the different liposomal formulations, obtained 
using in-vitro (PVPA) and ex-vivo (ENSPA) assays. These data show that THA 
encapsulation in liposomal formulations improved drug permeability. As can be 
observed in Figure 4.5, the presence of Toc in Lipo B and Ω3 in Lipo C further 
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Fig. 4.4  Percentage of THA remained on nasal mucosa after the application of THA solution, 
Lipo A, Lipo B, Lipo C and Lipo D at 30, 60, 90 and 120 minutes. Data are means ± SEM of four 
independent experiments. *p < 0.001 with respect to others liposome formulations, °p < 0.05 
with respect to others liposome formulations. 
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significantly improved THA permeability (p < 0.05) with respect to Lipo A. This 
behaviour suggests an enhancing effect of both tocopherol and poly-unsaturated fatty 
acids, when incorporated in the liposomal formulations. Moreover, this effect seems 
to be synergistic; in fact the best permeation profile and consequently the best PAPP 
was owned by Lipo D.  
 
 
THA permeability values obtained using ENSPA are reported in Fig. 4.5. These 
values were higher than those obtained with PVPA accordingly to the structural and 
functional differences between the barriers used in the two permeation assays. In 
fact, the phospholipid vesicle barriers used for PVPA consist of a stack of multiple 
bilayers, where drugs permeate exclusively via passive diffusion. On the contrary, 
the sheep nasal mucosa employed for ENSPA, represents a cellular barrier 
composed, which allows to measure not only transcellular passive diffusion but also 
Fig. 4.5  THA apparent permeability (PAPP, cm/s x 10
-6
) and THA permeability (P, cm/s x 10
-6
) 
evaluated using (PVPA) Phospholipid Vesicle based Permeation Assay and (ENSPA)  
Ex-vivo Sheep Nasal Permeation Assay, respectively.  Data are means ± SEM of  
six independent experiments.  *p < 0.05 vs THA solution,  °p < 0.05 vs Lipo A, 
 #p < 0.05 vs Lipo C and Lipo B. 
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paracellular passive diffusion and active transport. Although, the absolute 
permeability values were different for the two assays employed, permeability trend 
was very similar following the order: Lipo D > Lipo C ~ Lipo B > Lipo A ~ THA 
solution. Plotting the two data sets in a graph a good linear correlation (R
2
 = 0.9715) 
was obtained, indicating good comparability between the two methods (not shown). 
Furthermore, this behaviour indicates that THA permeability differences between the 
various liposomal formulations most likely are due to changes in the passive 
diffusion and the enhancing effect of Toc and/or Ω3 might be due to a modulation of 
barrier characteristics. 
 
 
 
4.3.5. THA neuronal uptake/association 
 
The main assumption for the direct transport across olfactory nerve to the central 
nervous system is drug absorption into olfactory neurons [167, 168]. This study was 
thus performed using neuronal cells with the aim to evaluate liposome ability to 
promote THA uptake/association. 
Fig. 4.6 shows THA associated level in human neuroblastoma SH-SY5Y cell line, 
after incubation with THA solution or with loaded liposomes. In particular, the 
amount of THA (expressed as nmol of THA recovered for mg of cellular protein) 
associated to neurons after treatment with THA solution, Lipo A, Lipo B, Lipo C and 
Lipo D, was: 0.42 ± 0.02 nmol/mg protein, 0.74 ± 0.04 nmol/mg protein, 0.93 ± 0.04 
nmol/mg protein, 0.82 ± 0.05 nmol/mg protein and 1.08 ± 0.05 nmol/mg protein, 
respectively. Data highlight that drug uptake/association was greater for THA loaded 
liposomes compared to THA solution (p < 0.001), confirming the results obtained 
with permeability studies and emphasizing the benefits to include drug in liposomal 
vesicles.  Significant difference in THA uptake/association is also present between 
the various liposomal formulations. Particularly, liposomes enriched with Toc (Lipo 
B and Lipo D) presented a greater uptake/association compared to Lipo A and Lipo 
C (p<0.05). Furthermore, it is possible to note that the concomitant presence of Toc 
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and Ω3 in Lipo D allowed obtaining the best uptake performance, confirming once 
again the synergistic enhancing effect of the two substances.  
 
 
 
 
4.4. Conclusions 
 
In summary, the presented data allow us to conclude that the inclusion of THA 
within liposomal formulations as well as the incorporation of Toc and/or Ω3 in the 
liposomal formulation enhances the permeability both across a phospholipid vesicle-
based permeation barrier and ex-vivo sheep nasal mucosa. Furthermore, the liposome 
formulation strategy resulted in enhanced mucoadhesion, making it promising for 
nasal administration. In addition to these features, Toc has promising antioxidant and 
neuroprotective effect (studied in detail in chapter 5). For these reasons, we can 
conclude that these new multifunctional liposomes may be potentially useful in AD 
treatment. 
Fig. 4.6  THA uptake in human neuroblastoma SH-SY5Y cell line. Data are reported as nmol of THA per 
mg of protein recovered in the supernatant of lysed cells and are means ± SEM of six independent 
experiments. *p < 0.001 vs THA solution, °p < 0.05 vs Lipo A and Lipo C, #p < 0.05 vs Lipo B. 
 
5. Multifunctional liposomes for delivery of the anti-Alzheimer drug tacrine hydrochloride by the 
nasal route. Part 2
 
 
   Giuseppe Corace                                   Page 92 of 130                                  University of Bologna      
 
 
 
5. MULTIFUNCTIONAL LIPOSOMES FOR DELIVERY OF THE ANTI-
ALZHEIMER DRUG TACRINE HYDROCHLORIDE BY THE NASAL 
ROUTE. PART 2: TOCOPHEROL LATERAL DIFFUSION AND 
NEUROPROTECTIVE EFFECT EVALUATION 
 
 
Fig. 5.1  Graphical Abstract. Multifunctional liposomes convey Tacrine Hydrochloride 
and also have an antioxidant effect due to the presence of Tocopherol                    
between their excipients. 
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5.1. Introduction 
 
Alzheimer’s disease (AD) the most common form of dementia among older people, 
is characterized by the breakdown of connections between neurons and their eventual 
death [169]. Neuropathological examination of the AD brain shows the presence of 
characteristic markers such as  intraneuronal neurofibrillary tangles (NFTs) 
composed of hyperphosphorylated tau protein and senile plaques, which are due to 
the deposition of amyloid-β peptides (Aβ), derived from the altered cleavage, 
operated by β-secretases (BACE1) and γ-secretases (proteic complex composed by 
Presenilin 1 (PS1) and 2 (PS2), and mature Nicastrin (APH-1)),  on the Aβ precursor 
protein (APP), resulting in over production and aggregation of neurotoxic forms of 
Aβ. The relationships between Aβ and the pathogenesis of the disease seems well 
established. In fact, Aβ aggregates are neurotoxic and also promote the  
hyperphosphorylation of tau protein, thus causing before neuronal dysfunction and 
subsequently neuron death [170-172]. Moreover, the possibility that soluble forms of 
Aβ, including profibrils and oligomers, may also be more toxic than Aβ, has recently 
been taken into account. In fact, the presence of soluble Aβ increases the caspases 
activation [173]. Caspases are a family of serine-aspartyl proteases whose activation 
normally leads to cell apoptosis.  Caspases are involved in the cleavage of numerous 
proteins, including APP, presenilin (PS1, PS2) and tau [174, 175], which, as 
mentioned above, are involved in AD. Recently, has been shown that their activation 
does not necessarily conduct neurons to the apoptosis process; in fact, caspases can 
be activated for long time without neuronal death [176] carrying out their deleterious 
actions on neurons and promoting the AD progression [177].  
Based on these notions, oxidative stress (OS) is increasingly taking a key role in the 
pathogenesis and progression of several neurodegenerative disorders including AD. 
OS and Aβ are closely intertwined; particularly, OS increases the production of Aβ 
[178], due to the increase of BACE1 and PS1 expression and activity [179], and Aβ 
promotes OS in-vivo and in-vitro [180], creating a vicious cycle that forwards the 
disease. In addition, is well known that reactive oxygen species (ROS) activate the 
caspases with everything that goes with it.  
Nowadays, the approved AD therapy is based on the administration of 
acetylcholinesterase (AChE) inhibitors (tacrine hydrochloride, rivastigmine and 
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donepezil) able to increase acetylcholine (Ach) levels in the cholinergic synapses 
[181]. Indeed, knowing the multifactorial nature of AD, would be desirable to 
combine the approved AD therapy  with the treatment of the OS, which is one of the 
most critical factor for the AD progression.  
Alpha-Tocopherol (Toc) is the primary form of vitamin E, one of the earliest-known 
and best-studied vitamins, which its major role is regarded to be as an antioxidant 
acting to prevent free radical damage to tissues and specifically to unsaturated lipids, 
which are particularly abundant in the brain [182-184]. In fact, brain is very 
vulnerable to OS due to its high oxygen consumption, high polyunsaturated fatty 
acids concentration and relatively low levels of antioxidants; this condition is much 
more pronounced in the elderly and in AD patients [178, 185].  
The inclusion of Toc in the liposome phospolipid bilayer has been extensively 
studied. Peter J. Quinn [186] has highlighted as Toc influences the stability reducing 
the drug leaking from liposomes. We reported in the first part of this article that 
liposomes encapsuling Toc can improve the mucoadhesion properties and 
permeability of THA, also increasing neuronal uptake. In addition to these vesicle 
structural improvements, the inclusion of Toc can enriches the function of liposomes, 
which would no longer be only a drug’s carrier but also antioxidant liposomes able to 
carry out a more protective action. This is extremely important, especially in those 
diseases where the OS is strongly implicated and where the reduction of drug toxicity 
is needed, such as in the AD [187-190]. 
Another important factor for the brain health is its content in docosahexaenoic acid 
(DHA). Researcher have established that when the brain is rich in DHA, production 
of senile plaques is lower, with a decrease of characteristic symptoms of the disease 
[191]. Other studies have highlighted that in the AD patients the DHA concentration 
in blood cell is very low, on the contrary was seen that the DHA breakdown products 
in the blood were very high, concluding that in AD, DHA is being destroyed, 
realising inflammatory breakdown products and consequently decreasing its 
concentration in the brain [192]. It has been reported that encapsuling marine 
phospholipids, which are rich in DHA and eicosapentaenoic acid (EPA), in 
liposomes their oxidation is reduced and their bioviability is increased [193]. 
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We suggest that antioxidant liposomes encapsulating a classical (AChE) inhibitors 
such as tacrine hydrochloride THA and enriched with DHA and EPA (Ω3) could be 
useful as a multifunctional therapy for the AD, increasing THA bioavailability and 
performing a neuroprotective action. In the present study we tested the 
neuroprotection ability of several liposome formulations, in particular, the ability to 
protect the neuroblastoma SH-SY5Y cell line against H2O2-induced oxidative injury 
was evaluated, measuring the reduction of intraneuronal ROS production and the 
inhibition of Caspase-3 activation, following liposomes treatment. 
The liposomes used have been previously prepared and characterized as regards drug 
loading, particle size, Z-potenzial, mucoadhesion to nasal mucosa, permeability and 
neuronal uptake. the results are reported in the chapter 4 of the thesis. 
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5.2. Materials and Methods 
 
 
 
5.2.1. Materials 
 
Tacrine hydrochloride (THA), α-tocopherol, L-α-phosphatidylcholine from egg yolk 
and cholesterol were purchased from Fluka (Milan, Italy). Eicosapentaenoic acid and 
docosahexaenoic acid were obtained from Doosan Serdary Research Laboratories 
(Englewood Cliffs, NJ). Egg phosphatidylcholine, Lipoid E-80, was kindly provided 
by Lipoid GmbH (Ludwigshafen, Germany). Triton X-100, calcein, CelLytic M, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 20,70 
dichlorodihydrofluorescein diacetate (DCFH-DA), H2O2, bovine serum albumin 
(BSA), dimethyl sulfoxide (DMSO), Dulbecco’s modified Eagle’s medium 
(DMEM), fetal calf serum (FCS), penicillin/streptomycin, were purchased from 
Sigma-Aldrich (Milan, Italy). Clear culture Transwell inserts (diameter 6.5 mm) and 
plates were obtained from Corning GmbH, Life Sciences (Wiesbaden, Germany). 
Clear Millicell cell culture plates (24 well) were purchased from Millipore A/S 
(Copenhagen, Denmark). All the solvents and salts were purchased from Carlo Erba 
(Milan, Italy). Phosphate buffer pH 6.0 and pH 7.4 had the following composition 
(g/L): 7.97 KH2PO4, 3.30 Na2HPO4*12H2O and 0.60 KH2PO4, 6.40 
Na2HPO4*12H2O, 7.42 NaCl respectively. 
 
 
 
5.2.2. Liposome Formulations and characterization 
 
 
The composition of liposome formulations investigated in this part of the study (Lipo 
A, Lipo B, Lipo C and Lipo D) is summarized in Table 1. These were prepared by a 
modified Reverse-Phase Evaporation Vesicles technique; preparation and 
characterization are described in detail in Part 1 of this study. In particular, liposomes 
presented a mean diameter of approximately 200 nm and a slightly negative Z 
potential; not significant difference was found between the different liposome 
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formulations. The functional properties of the liposome formulation are reported in 
Table 5.1 Data highlighted the advantages of THA encapsulation liposomes 
compared to THA solution; in fact, an improvement in terms of permeability, 
mucoadhesion and neuronal uptake/association can be noted. 
 
 
Table 5.1  Liposome formulations, Mean Diameter (),Zeta Potential (Z), THA Permeability (P), 
Mucoadhesion and Neuronal uptake/association (N) 
 
 Lipid Concentration 
(mM) 
THA 
Conc. 
(μM) 
 (nm) 
 
Z (mV) P                
(cm/s x 10
-6
) 
M N 
(nmol/mg 
protein) 
EPC Ω-3a Toc CHO     
Lipo A 9.60   6.40 285.3 181.8 ± 3.0 -14.0 ± 1.1 15.56 ± 0.6 ++ 0.74 ± 0.04 
Lipo B 9.60  2.08 4.32 304.9 192.4 ± 2.9 -14.5 ± 0.6 18.82 ± 1.0 +++ 0.93 ± 0.04 
Lipo C 9.60 2.08  4.32 308.8 179.3 ± 8.1 -16.2 ± 1.7 19.10 ± 0.9 +++ 0.82 ± 0.05 
Lipo D 9.60 2.08 2.08 2.24 313.3 219.3 ± 4.2 -16.8 ± 0.9 23.31 ± 0.8 +++ 1.08 ± 0.05 
THA 
Sol 
/ / / / / / / 14.51 ± 0.9 +/- 0.42 ± 0.02 
 
aΩ3 = 60% eicosapentaenoic acid (EPA), 40% docosahexaenoic acid (DHA); +++ excellent  
mucoadhesion, ++ good mucoadhesion and +/- poor  mucoadhesion 
 
 
 
5.2.3. Cell culture and treatments 
 
Human neuronal-like SH-SY5Y cells were routinely grown at 37°C in a humidified 
incubator with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FCS), 2mM glutamine, 100 U/ml 
penicillin and 100 mg/ml streptomycin, as previously reported [194]. Cells with 15–
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20 passages were used. To evaluate neuronal viability and ROS formation, the SH-
SY5Y cells were seeded in culture dishes (size 100 mm) at 1.0 x 10
6
 cells/dish. 
Experiments were carried out 24 h after cells seeding. SH-SY5Y cells were 
incubated for 24 h with different concentration of THA ( 0.01 μM, 0.1μM, 1μM and 
10μM) or with different volumes of loaded liposomes (Lipo A, Lipo B, Lipo C and 
Lipo D)/ml of medium (corresponding at a final THA concentration of 0.01 μM, 
0.1μM, 1μM and 10 µM). 
 
 
 
5.2.4. Determination of neuronal viability 
 
Neuronal viability in terms of mitochondrial activity was evaluated with the 
colorimetric MTT assay, as previously described [195]. MTT is a substrate for 
intracellular and plasma membrane oxidoreductase, and its reduction is an indication 
of cellular metabolic activity. Active mitochondria of living cells can cleave MTT to 
produce formazan, whose amount is directly related to the number of living cells. 
Briefly, after SH-SY5Y cells incubation for 24 h with THA solution or loaded 
liposomes (detail are reported in the paragraph 2.3), the SH-SY5Y cells were washed 
with Hank’s Buffered Salt Solution (HBSS) and then incubated with MTT (0.5 
mg/mL) in HBBS for 30 minutes. After removal of MTT and further washing, the 
formazan crystals were dissolved in DMSO. The amount of formazan was measured 
at λ = 595 nm with a microplate spectrophotometer (VICTOR3 V Multilabel 
Counter, Perkin-Elmer Wellesley, MA, USA). The mitochondrial activity as well the 
neuronal viability are expressed as percentage of control cells and calculated by the 
formula:  
 
(absorbance of treated neurons/absorbance of untreated neurons) x 100. 
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5.2.5. Intracellular ROS formation 
 
The intraneuronal ROS generation measurement was quantified with the fluorescent 
probe DCFH-DA as a well-established compound to detect and quantify intracellular 
produced H2O2. The test is based on the conversion, in several steps, of the 
nonfluorescent DCFH-DA to the highly fluoresecent compound 2’,7’-
dichlorfluorescein (DCF). First, DCFH-DA is transported across the cell membrane 
and deacetylated by esterases to form the non-fluorescent 2’,7’-dichlorfluorescein 
(DCFH). This compound is trapped inside of the cells. Next, DCFH is converted to 
DCF through the action of peroxid rated by the presence of peroxidise [196]. Briefly, 
after SH-SY5Y cells incubation for 24 h with THA solution or loaded liposomes 
(detail are reported in the paragraph 2.3), cells were incubated with 5 mM DCFH-DA 
in HBSS for 30 min in the dark. After DCFH-DA removal and further washing, the 
cells were treated with H2O2 200 mM for 30 min and fluorescence was measured 
using a microplate spectrofluorometer (VICTOR3 V Multilabel Counter, Perkin-
Elmer) (exc = 485 nm and λem = 535 nm). Data are expressed as percent of cells 
exposed only to H2O2, calculated by the formula:  
 
(Fluorescence of treated neurons/ Fluorescence of untreated neurons) x 100. 
 
 
 
5.2.6. Assessment of Neuroprotection  
 
Neuroprotection was qualitatively measured by the inhibition of Caspase-3 
activation; in fact, the activation of this enzyme is closely linked to apoptosis, and 
then to cell (neuron) death. Briefly, SH-SY5Y cells were seeded on 15 mm diameter 
glass cover-slips and were treated with 35 µL of loaded liposomes (Lipo A, Lipo B, 
Lipo C and Lipo D) / mL of medium (corresponding at a final THA concentration of 
10 µM) or THA solution (10 µM) for 24 h. Then, cells were treated with H2O2 200 
mM for 30 min and subsequently were fixed with 4% paraformaldehyde (PFA) in 
PBS, permeabilized for 5 min in 0.1% Triton X-100 (Sigma) in PBS and incubated 
overnight in 3% bovine serum albumin (BSA) in PBS containing the primary 
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antibody rabbit anti-activated caspase-3 1:500 (Chemicon, Millipore). Cells were 
then incubated for 2 h at room temperature with a secondary antibody conjugated 
with Alexa 546 (Invitrogen), mounted in Aqua Poly/Mount (Polysciences, Inc.), and 
analyzed by fluorescence microscopy. DAPI was used to visualize nuclei. 
 
 
 
5.2.7. Evaluation of α-Tocopherol intermembrane transfer 
 
Tocopherol intermembrane transfer was evaluated quantifying the amount of 
tocopherol diffused from the liposome formulation (A, B, C and D) to an acceptor 
system represented by Phospholipid Vesicle barrier (PVb) (barriers used for the in-
vitro permeability assay reported in detail in the Part 1 of this study). The permeation 
of free THA was used as negative control . Briefly, after phospolipid vesicle based 
permeation assay (PVPA), barriers were carefully washed, three times, with 
phosphate buffer pH 7.4; subsequently they were treated with 1 mL of 1% v/v triton 
X100 methanolic solution to break and to solubilize lipid vesicles. Finally, the 
amount of transferred tocopherol was determined by HPLC analysis [197]  using  a 
Waters 2695 HPLC with UV detection set at 295 nm (Waters 2487 Dual λ 
Absorbance Detector). Separation was performed by an Acclaim 120 (C18, 5 μm 
particle size, 120 Å, 4.6 mm × 250 mm) column. The mobile phase was composed of 
a mixture of methanol-water 98:2 (v/v) and the flow rate was 1.5 mL/min. The 
phospholipid concentration in the barrier was determined by colorimetric 
phospholipase D-based serum-phospholipid assay [198]. The experiments were 
performed six times for each loaded liposome formulation and THA solution. 
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5.3. Results and discussion 
 
 
 
5.3.1. Effect of THA and loaded liposomes on neuronal viability 
 
SH-SY5Y cells were treated with increasing concentration of THA in solution or 
loaded in liposomes ( 0.01 μM, 0.1μM, 1μM and 10μM) for 24 h to investigate their 
effect on neuronal viability. In Fig. 5.2 (.1, .2, .3, .4 and .5) data obtained by the 
MTT viability test are reported. From the data it can be deduced that THA solution, 
in the range of concentrations used in the test, was not neurotoxic. In fact,  the 
neuronal viability, expressed as percentage of control cells (untreated) at different 
THA concentration, was always close to 100%, without significant difference. Also 
the loaded liposomes (Lipo A, LipoB, Lipo C and Lipo D) at the same THA 
concentrations used for the test with THA solution, were not neurotoxic being 
neuronal viability close to 100%.  
 
 
 
Fig.  5.2.1   MTT assay of THA sol. Cells were exposed to different THA concentrations  (0-10 µM) for         
24 h. Cell viability was assessed by MTT reduction. Cell viability is comparable to control cells C(-). Data 
are means ± SEM of  six independent experiments. 
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Fig. 5.2.2   MTT assay of Lipo A. Cells were exposed to Lipo A with the same content in  THA (0-10 µM) 
for 24 h. Cell viability was assessed by MTT reduction. Cell viability is comparable to control cells C(-). 
Data are means ± SEM of six independent experiments. 
 
 
 
 
 
Fig. 5.2.3   MTT assay of Lipo B. Cells were exposed to Lipo B with the same content in  THA (0-10 µM) 
for 24 h. Cell viability was assessed by MTT reduction. Cell viability is  comparable to control cells C(-). 
Data are means ± SEM of six independent experiments. 
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Fig. 5.2.4   MTT assay of Lipo C. Cells were exposed to Lipo C with the same content in  THA (0-10 µM) 
for 24 h. Cell viability was assessed by MTT reduction. Cell viability is   comparable to control cells C(-). 
Data are means ± SEM of six independent experiments. 
 
 
 
 
 
 
Fig. 5.2.5   MTT assay of Lipo D. Cells were exposed to Lipo D with the same content in  THA (0-10 µM) 
for 24 h. Cell viability was assessed by MTT reduction. Cell viability is comparable to control cells C(-). 
Data are means ± SEM of six independent experiments. 
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In addition to the non toxicity of the excipient used to prepare liposome, preparation 
techniques and operating parameters appear suitable; in fact usually, one of the main 
issues concerning liposomes is their toxicity due to the residues of organic solvent 
used during preparation steps [199]. These solvents not only affect the chemical 
structure of the entrapped substance but can also remain in the final liposome 
formulation and contribute to toxicity and influence the stability of the vesicles [200-
202]. On this basis, we can suppose that the operating parameter adopted during 
liposome preparation, allowed to completely remove the organic solvent (diethyl 
ether) from the formulation. 
 
 
 
5.3.2. Effect of THA solution and loaded liposomes on intracellular ROS 
production 
 
Liposomes were enriched with Toc for its antioxidant properties and in general to 
produce a vesicle  system capable non only to convey THA to CNS but also 
characterized by additional function such as antioxidant and neuroprotective effect, 
thus obtaining multifunctional liposomes. To investigate the ability of our liposome 
formulation to reduce intracellular oxidative stress,  SH-SY5Y cells were pre-treated 
with THA solution or loaded liposomes  (THA concentration =  0.01 μM, 0.1μM, 
1μM and 10μM) for 24 h, prior to the addition of H2O2 (200 mM, 30 min) and the 
level of intracellular ROS was determined using the peroxide-sensitive fluorescent 
probe DCFH-DA. As expected, THA solution at different concentration, Lipo A 
(classical liposome formulation) and Lipo C (Liposome formulation enriched with 
Ω3) pre-treatment not reduced the intracellular ROS production following exposure 
to peroxide Fig. 5.3 (.1, .2, .3, .4 and .5). Indeed, with high concentration of 
liposomes a non significant increase of ROS generation was observed, which might 
be due to the phospholipids peroxidation by H2O2. On the contrary, pre-treatment 
with Lipo B and especially LipoD promoted a statistically significant decreases of 
intracellular ROS production induced by H2O2. This effect was strictly linked to the 
amount of liposomes used; particularly, for a THA concentration of 10μM 
corresponding to lipid concentration of 0.56 mM, the reduction due to pre-treating 
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with Lipo B and Lipo D was 35% and 50%, respectively. Data highlighted that Lipo 
D had a significant higher antioxidant activity than Lipo B, although the Toc 
concentration in both liposome formulation was the same. The reasons for this 
unexpected result might be due to a different Toc intermembrane transfer (see 
paragraph 5.3.4.).   
 
 
 
 
Fig. 5.3.1.   ROS production (DCFH-DA assay) THA Sol.  Cells were exposed to different THA 
concentrations  (0-10 µM). After 24 cells were stressed with H2O2 200 µM (30 min). ROS production is 
espressed as percentage of H2O2 treated (0) cells. THA pretreatment is not able to reduce ROS production. 
Data are means ± SEM of six independent experiments. 
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Fig. 5.3.2   ROS production (DCFH-DA assay) Lipo A.  Cells were exposed to Lipo A with the same content 
in  THA (0-10 µM). After 24 cells were stressed with H2O2 200 µM (30 min). ROS production is espressed 
as percentage of H2O2 treated (0) cells. Lipo A pretreatment is not able to reduce ROS production. Data 
are means ± SEM of six independent experiments. 
 
 
 
 
 
 
Fig.  5.3.3   ROS production (DCFH-DA assay) Lipo B.  Cells were exposed to Lipo B with the same 
content in  THA (0-10 µM). After 24 cells were stressed with H2O2 200 µM (30 min). ROS  production is 
espressed as percentage of H2O2 treated (0) cells. Lipo B significantly reduce  the ROS formation induced 
by H2O2. Data are  means ± SEM of six independent experiments. *p < 0.001 vs H2O2 treated (0) cells 
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Fig. 5.3.4   ROS production (DCFH-DA assay) Lipo C.  Cells were exposed to Lipo C with the same content 
in  THA (0-10 µM). After 24 cells were stressed with H2O2 200 µM (30 min). ROS production is espressed 
as percentage of H2O2 treated (0) cells. Lipo C pretreatment is not able to reduce ROS production. Data 
are means ± SEM of six independent experiments. 
 
 
 
 
Fig. 5.3.5   ROS production (DCFH-DA assay) Lipo D.  Cells were exposed to Lipo D with the same content 
in  THA (0-10 µM). After 24 cells were stressed with H2O2 200 µM (30 min). ROS  production is espressed 
as percentage of H2O2 treated (0) cells. Lipo D significantly reduce  the ROS formation induced by H2O2. 
Data are  means ± SEM of six independent experiments. *p < 0.001 vs H2O2 treated (0) cells 
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5.3.3. Assessment of Neuroprotection  
 
Caspase-3 protein is a member of the cystein-aspartic acid protease family. 
Sequential activation of caspases plays a central role in the execution-phase of cell 
apoptosis. It is the predominant caspase involved in the cleavage of amyloid-beta 4a 
precursor  protein, which is associated with neuronal death in Alzheimer’s disease. 
Since many studies have established the involvement of hydrogen peroxide in  
apoptotic SH-SY5Y cell death [203-205]. We investigated qualitatively whether 
loaded liposomes (Lipo A, LipoB, Lipo C and Lipo D) were able to reduce peroxide-
induced caspase-3 activation in SH-SY5Y cells [Fig. 5.4 (.1, .2, .3, .4, .5 and .6)]. In 
Fig. 5.4.1  can be noted that in the absence of oxidative stress, the enzyme was not 
activated, while after treatment with H2O2 (200 mM), a strong activation was 
observed (Fig. 5.4.2). Lipo A and Lipo B pre-treatment not reduced significantly the 
caspase-3 activation (Fig. 5.4.3, Fig. 5.4.4), while Lipo B and especially Lipo D 
almost completely reduced the enzyme activation; in fact, in Fig. 5.4.5 and Fig. 5.4.6 
is possible to note that red halo, corresponding to caspase-3 active, is almost absent 
as in the control (Fig. 5.4.1), highlighting the neuroprotective effect possessed by the 
two liposomes formulation. Should also be noted that Lipo D showed a higher 
neuroprotective activity compared to Lipo B, probably due to a higher antioxidant 
action performed by Lipo D (see paragraph 5.3.4.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.4.1 SH-SY5Y cells no stressed with 
H2H2. Caspase-3 no activated. 
Fig. 5.4.2 SH-SY5Y cells, stressed with H2H2. 
Caspase-3  activated. (Red Halo) 
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Fig. 5.4.3 SH-SY5Y cells pre-treated with 
Lipo A (24 h) and after stressed with H2H2. 
Lipo A pretreatment is not able to reduce 
Caspase-3 activation 
Fig. 5.4.4 SH-SY5Y cells pre-treated with 
Lipo B (24 h) and after stressed with H2H2. 
Lipo B pretreatment significantly reduces 
Caspase-3 activation 
Fig. 5.4.5 SH-SY5Y cells pre-treated with 
Lipo C (24 h) and after stressed with H2H2. 
Lipo C pretreatment is not able to reduce 
Caspase-3 activation 
Fig. 5.4.6 SH-SY5Y cells pre-treated with 
Lipo D (24 h) and after stressed with H2H2. 
Lipo D pretreatment significantly reduces 
Caspase-3 activation 
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5.3.4. Evaluation of Toc intermembrane transfer 
 
 
The intermembrane transfer of Toc was evaluated to explain the antioxidant and 
neuroprotective properties of  liposome formulations (Lipo A, Lipo B, Lipo C and 
Lipo D). In particular, this study was done to explain why Lipo D and Lipo B had 
different antioxidant activity, even if the amount of Toc contained in the two 
liposome formulations was the same.  
Fig. 5.5 shows the amount of Toc associated to the Phospholipid Vesicle barrier 
(PVb) after permeation assay “acceptor liposome”.  In particular, the amount of Toc 
(expressed as nmol of Toc recovered for mg of phospholipids) associated to PVb 
after treatment with THA solution, Lipo A, Lipo B, Lipo C and Lipo D, was: 0.45 ± 
0.03 ng/mg phospholipids, 0.59 ± 0.01 ng/mg phospholipids, 1.37 ± 0.03 ng/mg 
phospholipids, 0.69 ± 0.02 ng/mg phospholipids and 2.03 ± 0.06 ng/mg 
phospholipids, respectively. The amount of Toc recovered after THA permeation 
was considered as negative control; in fact, Toc contained as preservative in Lipoid 
E80 used to prepare the PVb. Moreover, the Toc recovered after Lipo A and Lipo C 
permeations was that contained in the manufacturing excipients as preservative         
(L-α-phosphatidylcholine from egg yolk, Fluka; Eicosapentaenoic acid and 
docosahexaenoic acid, Doosan Serdary Research Laboratories), in addition to that 
contained in the PVb. Indeed, the amount of Toc recovered after Lipo B and           
Lipo D permeations, correspond to that added in the liposome formulations                 
(“donor liposomes”) during liposome preparation, in addition to that contained in the 
PVb and in the manufacturing excipients. Data highlight that Toc intermembrane 
transfer was greater for Toc encapsulated in Lipo D compared to that in                  
Lipo B (p < 0.001), confirming the results obtained by Kagan, V.E. et al., which 
found that Toc intermembrane transfer efficiency was greater when “donor 
liposomes” contained unsaturated phospholipids [206].  
This effective transfer of Toc explains way Lipo D presented the best antioxidant and 
neuroprotectve activity. Practically, Ω3 increase the Toc transfer, thereby improving 
antioxidant effectiveness.   
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Fig. 5.5   Toc intermembrane transfer. Amount of Toc transferred to Phospholipid Vesicles 
barrier (PVb) as a result of THA Sol or Lipo (A, B, C and D) permeations, expressed as  nmol of 
Toc recovered for mg of phospholipids. Data are means ± SEM of six independent experiments.  
*p < 0.001 vs THA solution,  °p < 0.001 vs Lipo B 
 
 
 
 
5.4. Conclusion 
 
 
As general sum up, all these data allow us to conclude that the inclusion of Toc (Lipo 
B) and especially of Toc and Ω3 (Lipo D) in the liposomal formulation provided 
several advantages. These formulation strategy permitted to obtain liposomes with 
excellent antioxidant and neuroprotective activity. These properties have to be added 
to those relating to the conveyance to the CSN through the nasal mucosa, reported in 
the chapther 4. In conclusion, we can say that these new multifunctional liposomes 
are potentially useful in AD treatment, combining the traditional therapies strategy 
based on administration of acetylcholinesterase inhibitors (Tacrine hydrochloride) 
with the treatment of oxidative stress. 
6. Concluding Remarks 
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6. CONCLUDING REMARKS 
 
 
Alzheimer’s disease is multifactorial and heterogeneous neurodegenerative disease, 
involves several etiopathogenic mechanisms. It is irreversible disorder clinically 
characterized by abnormal memory loss along with deterioration of other cognitive 
abilities as well as motor capacities. AD is a progressive and disabling disorder, 
which affects particularly the elderly population and is the fourth main cause of death 
among people over 65 years old in industrialized countries. At present, there are no 
therapeutic interventions able to stop the progression nor to treat brain degeneration. 
The only marginal beneficial treatment currently achievable involves the 
enhancement of cholinergic neurotransmission, while the neurodegenerative process 
continues unabated. This is despite thousands of research articles and copious 
knowledge of molecular cascades that are presumed pathogenic. On the basis of its 
multifactorial nature, it seems likely that the next major advance will occur either as 
a multidisciplinary multimodality approach, attacking every conceivable facet of 
neurodegeneration.  
One of the main limitations of the new active molecules synthesized against AD is 
their poor bioavailability and especially their inability to cross the BBB. To 
overcome these limitation a new route of administration was taken in account in this 
thesis, the nasal route, which present numerous advantages compared to traditional 
oral route. In addition nasal route allows to convey drug administered directly in the 
CNS through the olfactory region. On the other hand this alternative route of 
administration present some limitations relative to physio-anatomical characteristics 
of the nose such as the high mucociliary clearance that removes in a few minutes the 
particulates, which are deposited on the mucosa. For this reasons, a drug to be 
administered by the nasal route has to be inserted in a particular formulation, capable 
of prolonge residence time of the drug by means of mucoadhesive properties and at 
same time enhance drug permeability. In this thesis two formulations were produced 
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and analyzed. The first project was to produce Albumin nanoparticles carrying 
cyclodextrin.  The results obtained highlithed that these nanoparticles carrying native 
and hydrophilic derivatives CD can be employed for the formulation of 
mucoadhesive nasal formulations with interesting drug permeation properties. The 
selection of suitable CD during particle preparation allows the modulation of their 
mucoadhesion ability and THA permeation at the administration site. 
The second project was to produce Multifunctional liposomes. These liposome 
formulation was conceived on the basis of the AD multifactorial nature; in particular, 
on the basis of the knoeledge that oxidative stress plays a key role in the 
pathogenesis of AD. So liposomes were produced combining the traditional therapies 
strategy based on administration of acetylcholinesterase inhibitors (Tacrine 
hydrochloride) with the treatment of oxidative stress. Results were very interesting; 
in fact, these new nanocarriers were found not only to improve mucoadhesion on the 
nasal mucosa but also to increase THA permeability. In addition, studies conducted 
on neuronal cell showed an excellent antioxidant and neuroprotective effect.  
Finally, is very important to note the new “formulative philosophy”, adopted to 
produce these liposomes; practically, the antioxidant effect is due to the Tocopherol, 
which was added as excipient in the formulation. This upsets the classical concept of 
excipient which is no more a simple envelope of the drug but becomes itself an 
active molecule contribuiting with the drug to achieve the therapeutic effect.  
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